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ABSTRACT 
IDENTIFICATION AND BIOCHEMICAL CHARACTERIZATION OF THE 
CHLAMYDIA TRACHOMA TIS TYPE III SECRETION CHAPERONE, SLCl, 
AND ITS ROLE IN THE TRANSLOCATION OF THE INVASION-
ASSOCIATED EFFECTOR T ARP 
Amanda Brinkworth 
May 2011 
Chlamydia trachomatis is an obligate intracellular pathogen that utilizes a type III 
secretion system to enter mammalian cells and establish an intracellular niche. TARP, 
the translocated ~ctin recruitment 12rotein, is a chlamydial invasion protein known to be 
type III secreted by the metabolically inert elementary body upon docking to the 
mammalian cell surface. Because immediate secretion of TARP into host cells is 
necessary for entry, I hypothesized that a chlamydial chaperone binds to TARP and 
facilitates its translocation through the type III secretion apparatus. Most effector-
binding type III secretion chaperones are small (14-18 kDa), have an acidic pI, and share 
a specific secondary structure of alternating alpha-helices (a) and beta-sheets (~). 
Typically, type III secretion chaperones dimerize and interact with their effectors as a 
complex of two molecules of chaperone to one effector molecule. Only 3 Chlamydia 
trachomatis proteins have been identified in EB' s that are predicted to be putative 
chlamydial type III effector chaperones. These are CT043, CT663, and CT088, which I 
have designated as SIc 1, SIc2, and Scc 1, respectively. These chaperones were tested for 
their interaction with the N-terminal200 amino acids ofTARP (HIS6_TARpl-200) by co-
v 
immunoprecipitation. HIS6- TARp
l-200 interacted specifically with SlcI, but not Scc1 or 
Slc2. This interaction was enhanced by coexpression of the recombinant proteins. To 
confirm this interaction and rule out the possibility of Slc 1 heterodimerization enhancing 
the interaction with TARP, I employed a 2-hybrid system to test for TARP: chaperone 
and chaperone:chaperone interactions. I confirmed the specific interaction between 
CyalS-TARp l-200 and Cya2S-Slc 1. I was also able to detect SIc1 interaction with itself as 
well as confirm a few other previously described chaperone-chaperone interactions. 
Analysis by crosslinking and gel filtration chromatography indicated that Slc 1 forms a 
stable dimer in solution. Complexes of the Slci chaperone dimer with TARP in a 2:1 
stoichiometry were detected following purification from co-expressing bacteria, but not 
following addition of singly purified species. Expression ofbeta-Iactamase fused to 
TARpl-200 by the heterologous system Yersinia enterocolitica allowed for secretion of 
TARP into type-III inducing media (low calcium). Furthermore I was able to detect 
SIc I-dependent translocation of T ARP into HeLa cells via the heterologous type III 
secretion system of Y enterocolitica, and also by the SPI-2 system of Salmonella 
enterica serovar typhimurium. 
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Epidemiology 
CHAPTER I 
INTRODUCTION 
A myriad of diseases are caused by pathogenic Chlamydia species that can 
efficiently invade human mucosal epithelial cells. Genital infections of the superficial 
mucosal epithelium in the endocervix or urethra by serovars D-K can result in cervicitis, 
urethritis, endometritis, salpingitis, and proctitis. LGVl-3 of C. trachomatis are 
responsible for invasive genital infections that result in lymphogranuloma venereum, and 
serovars A-C are responsible for ocular infections that can result in blinding trachoma. 
Lung infections with C. pneumoniae or C.psittaci can result in mild upper respiratory or 
life-threatening pneumoniae, respectively. Chlamydial infections are also endemic to 
koalas, guinea pigs, mice, sheep, and cattle. 
Chlamydia is the most common bacterial sexually transmitted disease in the 
United States. Most Chlamydia infections are asymptomatic, allowing the bacteria to 
persist in the genital tract until it is cleared naturally by the host immune system. In a 
small fraction of infected females, long-term complications such as pelvic inflammatory 
disease (PID), ectopic pregnancy, and tubal infertility occur[l]. An extensive survey of 
Chlamydia genital infections in 2007 was reported by the Center for Disease Control 
(CDC) and they estimated over 1.1 million infections in the U.S. Their most convincing 
findings were from the screening of the National Job Training applicants that reported 
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infection rates of 13.2% of females and 7.2% of males aged 16-24 year olds Were 
positive for C. trachomatis infections[2]. Furthermore the World Health Organization 
has estimated over 90 million cases of C. trachomatis infection worldwide[3], with 
serovars D, E, and F being the most prevalent[4, 5]. 
C. trachomatis is also the causative agent of blinding trachoma that accounts for 
16% of blindness worldwide. Ocular infection mainly affects young children (0-4 yrs 
old) and is cleared without complications within 2-4 weeks. However familial transition 
to adults can result in serious scarring of the tarsal conjunctiva, inversion of the eyelid, 
and corneal scarring due to scratching by the in-turned eyelashes. Without treatment, 
continued irritation by chlamydial antigens will lead to corneal opacity and eventually 
blindness[6]. Trachoma is mainly a disease endemic to poverty-stricken villages with 
little access to clean water and medicine. 
The World Health Organization currently funds a campaign to eradicate blinding 
trachoma by 2020 that utilizes the SAFE strategy (.s.urgery, Antibiotic treatment, facial 
cleanliness, and Environmental improvement)[7]. Some advanced ocular infections 
require eyelid surgery in addition to antibiotic treatment to prevent blindness. Treatment 
with tetracycline derivatives (doxycycline) or macrolides (erythromycin, azithromycin) is 
sufficient to clear up most C. trachomatis infections. Mass treatment with antibiotics has 
been proposed to eradicate trachoma within specific communities, but evidence of 
pneumococcal resistance to these antibiotics has emerged as a major barrier to mass 
treatment strategies[8]. 
C. pneumoniae is responsible for 10% of mild upper respiratory infections. It has 
been estimated that 80% of people will have had C. pneumoniae infection in their 
2 
lifetime[9]. C. pneumoniae has also been found in the joints and in atherosclerotic 
plaques, associating the bacterium with chronic inflammatory diseases as well[l 0]. 
Chlamydia pathogenesis 
The ability of Chlamydia trachomatis to cause damage to human tissues is a 
consequence of the host immune response to infection. Clearance of C. trachomatis 
genital infections involves a combination of innate and cellular immune responses[ll, 
12] The housekeeping gene, heat-shock protein 70 (Hsp70), from Chlamydia species is 
recognized by host cell toll-like receptors TLR2 in cooperation with CD14 to induce 
secretion of the pro-inflammatory cytokine IL-8 (interleukin-8)[13]. Initial infection of 
human epithelial cells results in the release of pro-inflammatory cytokines such as IL-l p, 
IL-6, GM-CSF (granulocyte-macrophage colony stimulating factor) and TNF (tumor 
necrosis factor) that attract monocytes, natural killer cells and neutrophils, as well as in 
releasing tissue-damaging matrix-metalloproteases (MMPs)[l, 13]. These recruited cells 
further release damaging MMP's, elastase, and secrete IFN-y (interferon-gamma) to drive 
a Thl-like CD4+ T-cell response. Further mediators of cellular immunity (CD8+ T-cells, 
B cells, and plasma cells) are recruited to the site of infection and secrete IFN-y which 
activates IDO (indoleamine-2,3-dioxygenase) and subsequently blocks synthesis of 
tryptophan in RBs [1, 12]. 
Treatment ofRB's with IFN-y, Penicillin, or nutrient or iron starvation in cell 
culture induces a "persistent" non-dividing, but transcriptionally active state. Under 
these conditions the RBs become enlarged while persisting as an "abberant" RB that can 
survive inside the host cell for extended periods of time. The fact that these RB' s can be 
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recovered from their persistent state and continue their developmental cycle upon 
removal of the persistence-inducing stimuli hints at possible role for developmental 
persistence in long-term "silent" chlamydial infections[14]. 
Decreased organismalload and decreased duration of repeat Chlamydia 
trachomatis genital infections indicate the induction of adaptive immunity [9, 15, 16]. 
Interestingly, repeat infections are common and more likely to result in long-term 
complications indicating that any acquired immunity is incomplete [17]. Host factors 
such as HLA-DR alleles and IL-1 0 promoter polymorphisms are also associated with 
clearance of the pathogen by influencing the ability of the infected persons to mount an 
effective Thl immune-response[18]. 
In a minority of infections, the host immune response induces fibrosis and 
scarring of the fallopian tubes that are responsible for tubal infertility and ectopic 
pregnancy[l, 11]. However, it is still unclear which immune cells are responsible for 
infection-associated morbidity. Several studies have identified reduced IFN-y production 
by CD4+ T-cells and Peripheral Blood Mononuclear Cells (PBMC's) as an indicator of 
tissue damage and long-term sequelae.[19-21]. 
The challenge of designing a vaccine for immunization against Chlamydia 
trachomatis would be to initiate a bacteria-clearing Th1-response while avoiding a tissue-
destructive inflammatory response in individuals with previous Chlamydia infections[ll, 
16]. In fact, a dead-whole cell vaccine against ocular Chlamydia trachomatis infections 
was administered in the 1960's, which was effective in some individuals, while damaging 
to those who were re-infected[ 16]. Furthermore, an ideal vaccine would integrate 
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chlamydial antigens that would elicit an effective immune response against all pathogenic 
Chlamydia species. 
Adaptation ofpathogenic Chlamydia to their mammalian hosts 
Comparison of ribosomal RNA from Chlamydiae with that of other modem 
prokaryotes indicates a divergence of Chlamydiae from Proteobacteria and other 
prokaryotes nearly 2 billion years ago. Pathogenic and environmental species of the order 
Chlamydiae are obligate intracellular prokaryotes that split about 700 million years ago. 
Environmental species reside within unicellular eukaryotes such as free-living amoeba 
and are ubiquitous in nature. Differences between the genome of the recently 
characterized Acanthameoba environmental strain UI25 and those of modem pathogenic 
species have provided insight into the adaptation of pathogenic family Chlamydiaceae to 
their niche in the mammalian cell. 
The genome of the UWE25 strain is more than twice the size (~2.4 million) of 
those of the pathogenic strains (~1 million bp), while a core set of 711 CDS were 
conserved among these strains. Adaptation of the pathogenic Chlamydia to mammalian 
hosts involved a drastic reduction (~2000 CDS to 1000 CDS) in genes, many of which 
encoded proteins involved in biosynthetic and metabolic pathways. Pathogenic species 
are auxotrophic for most amino acids and nucleotides and compete with their host cells 
for them. Other adaptations unique to pathogenic Chlamydia include genes encode 
possible bacterial adhesins: the major outer membrane protein, MOMP (ompA) and the 
polymorphic outer membrane proteins (Pmps). These additions to the pathogenic 
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chlamydial surface likely playa role in attachment to specific host cell types and/or 
immune evasion[22]. 
However, the cysteine-rich outer membrane proteins OmcA and OmcB that make 
up Chlamydia's unique disulfide-bonded outer membrane are present in UI25. Unlike 
other gram-negative bacteria, Chlamydia do not synthesize a peptidoglycan layer on their 
surface for structure, instead highly crosslinked protein complexes of OmcA, OmcB, and 
MOMP provide stability and protect EB's from environmental stress[23]. Conserved 
genes between UI25 and modem pathogenic Chlamydia indicate the importance of their 
gene products for maintaining intracellular survival. In addition to the outer membrane 
proteins (OmcAB), these conserved genes encode some inclusion membrane proteins 
(Incs), components of the type III secretion system (T3SS), as well as some type III 
secretion effectors. 
Type III Secretion 
Type III Secretion Systems are syringe-like molecular machines that are common 
in pathogenic and non-pathogenic gram-negative bacteria and transport specific bacterial 
proteins into eukaryotic cells. Pathogenic bacteria often utilize type III secretion systems 
deliver effectors that hijack cellular functions such as reorganizing the host cytoskeleton, 
modulating immune signaling or apoptotic factors. A more detailed discussion of type III 
effector functions will be discussed later. A functional type three secretion system 
consists of structural components that make up the inner and outer membrane base, the 
needle shaft, tip, and translocator proteins[24]. It also requires cytoplasmic chaperones 
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and a membrane bound ATPase to effectively stabilize and deliver effector proteins, 
respectively. 
These components of Type III Secretion Systems remain conserved across gram-
negative species and also share close structural homology with flagellar components. 
Such structural conservation has allowed for the quick identification of putative 
chlamydial type III secretion proteins in silica analysis based on conserved structural and 
genetic domains[25-31]. Many groups have identified putative Chlamydia TTSS 
components by these approaches, but because of Chlamydia species' genetic 
intractability, it has remained a challenge to confirm the function of these proteins. Most 
of our current knowledge of the structure of the chlamydial type III secretion apparatus 
comes from the discovery of in vitro protein-protein interactions between chlamydial 
type III components.[27, 32-41], while the detection of new chlamydial effectors has 
involved expression and secretion of recombinant chlamydial proteins in heterologous 
type III secretion systems of other bacteria[3 8, 40-43]. The predicted structure of the 
Chlamydia type III secretion apparatus and its components is visualized in Figure 1. 
Assembly of the chlamydial type III apparatus begins with sec-dependent 
secretion of CdsC, an outer membrane lipoprotein with homology to secretins[ 44] 
followed by secretion of CdsJ into the inner membrane [ 45], and then CdsD into the 
integral membrane to join the former components into a scaffold that spans two bacterial 
membranes[31]. CdsD homo logs in other bacteria function as scaffolding proteins to link 
CdsC and other integral membrane components. CdsD has been shown to co-
immunoprecipitate with other integral membrane proteins as expected[36], but unique 
features such as forkhead association domains (FHA) and in vitro phosphorylation are 
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puzzling as to the actual role of CdsD in type III secretion[ 46, 47]. Homology with inner-
membrane components from Yersinia species indicate that CdsJ provides a scaffold for 
the inner membrane components CdsRlS/T/U and V[46]. CdsS and CdsT interact with 
the C-ring component CdsQ, while the CdsU homolog in Yersinia Y scU gets cleaved to 
allow secretion[ 48]. CdsD has been shown to interact with the cytoplasmic ATPase 
CdsN and with CdsL, a possible negative regulator of ATPase activity[35]. A complex 
network of interactions has been shown to occur in vitro between CdsQ, CdsD, CdsN, 
and CdsL [35,49]. Upon assembly of the inner membrane and C-ring components, the 
machinery becomes secretion competent and secretes its needle subunits CdsF[27], 
possibly with the help of the putative molecular ruler protein CdsP[50]. Lastly secretion 
of the tip protein, identified as CT584 in C. trachomatis, completes the latent type III 
secretion apparatus and is likely to be responsible for activating secretion upon host cell 
contact[34]. CopN interacts with the ATPase CdsN and prevents secretion of any 
effectors [ 41, 51] 
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Eukaryotic cell membrane 
Outer membrane 
Inner Membrane 
Figure 1. The Type III Secretion System of Chlamydia. 
The chlamydial cds components C-V correspond to their ysc homologues in Yersinia. 
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Interaction of the chlamydial EB with the host cell is sensed by the tip protein, 
which in tum relays an unknown signal to induce CopN secretion. Unblocked, the type 
III apparatus secretes pairs of trans locator proteins (CopB/CopD or CopB2/CopD2) to the 
end of the needle such that they can form a pore in the host cell membrane[37, 38, 46]. 
After secretion of CopN and the translocator proteins, the ATPase is free to interact with 
effectors and ensure their translocation into the host cell. 
It must be noted however that several of the secreted components and effectors 
require or utilize molecular chaperones to be efficiently secreted. Bacterial type III 
secretion chaperones have been organized into classes based on the type of substrates 
with which they interact. Class I chaperones mediate the translocation of type III 
effectors and are typically small (13-16 kDa), have an acidic pI (4-5), and have a 
tendency to dimerize. CT043, CT088 (also called Scc1), and CT663 have been predicted 
to be Ctrachomatis class I chaperones based on their predicted secondary structure[28, 
29,52], but to date their interaction with effector proteins has not been confirmed. A 
recent yeast-2-hybrid screen identified an interaction between CT663 and CT088, 
indicating formation of a chaperone heterodimer[ 49]. The same screen also identified a 
new class Ib chaperone that was capable of interacting with multiple effectors as well 
with the C-ring component CdsQ which was described as the multi-fargo ~ecretion 
fhaperone, Mcsc. Characterization of Mcsc by crosslinking also indicated a 
homodimeric molecular structure. In addition, CT663 has been shown to interact with 
region 4 of the sigma-66 subunit of Chlamydia and the p-subunit of E. coli RNA 
polymerase in a fashion typical of anti-sigma factors[53]. 
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The translocator proteins are secreted by Class II chaperones which have 
tetratricopeptide repeat (TPR) regions. In Chlamydia trachomatis the TPR-containing 
chapeorones Scc2 and Scc3 are transcribed in operons with their sets of translocators, 
CopB lICopD 1 and CopB2/CopD2, respectively. Scc2 has been demonstrated to interact 
with both CopB 1 and CopD 1, but unexpectedly Scc3 has been shown to interact with 
CopN, the type III secretion-negative regulator. A third TPR-containing protein, CT274, 
has been detected in Chlamydia spp. and its small size and acidic pI indicate that it may 
have chaperone function. Novel interactions between CT274 and the hypothetical 
proteins CT668 and CT166 indicate possible Chlamydia-specific type III related proteins. 
Type III chaperones that are responsible for the stability or secretion or type III 
components other than effectors or translocators have been classified as Class III 
chaperones[ 46]. The needle subunit CdsF and molecular ruler protein CdsP have been 
demonstrated to interact with chaperone products from their respective operons, cdsEFG 
and cdsOP. A yeast-3-hybrid assay indicated that CdsE and CdsG form a heterodimer 
that can interact with CdsF[27]. Multiple studies have identified an interaction between 
CdsP and its putative chaperone CdsO[33, 54]. Furthermore, CdsO was shown to form 
homodimers indicative of type III chaperones. Predicted and experimentally confirmed 
type III secretion chaperones and their substrates are summarized in Table 1. 
Many roles have been reported for the interaction of Class I type III secretion 
chaperones with their cognate substrates. The most popular role for a Class I chaperone 
has been to bind approximately the 30-130 N -terminal amino acids of its cognate effector 
and to unfold the adjacent N-terminal secretion signal. Some chaperones have also been 
demonstrated to increase the solubility of their substrates or prevent their degradation[55-
11 
58]. Directly mediating the interaction between the effector and ATPase has also been 
reported[59,60]. Less common functions have included blocking secretion-inhibitory 
domains or cnzymatic domains of effectors [ 61, 62]. 
Many pathogenic bacteria such as Salmonella, E.coli, Shigella, Pseudomonas, and 
Yersinia species utilize type III secretion systems to export virulence factors into target 
cells[63]. In these bacteria, the type III secretion-related genes are mostly located in 
pathogenicity islands or on specific virulence plasmids. However most type III genes in 
Chlamydia are spread out among ten operons while a few other type III-related genes are 
completely separate in the genome. In fact this disjointed type III structure is conserved 
among environmental Chlamydia isolates[64]. Approximately 10% of the Chlamydia 
trachomatis serovar D genome is annotated to be type III secretion-related. Considering 
the small size of the genome it is likely that these are all functional and necessary for 
productive infection. 
In addition to type III secretion components, Chlamydia also contains an 
incomplete set of flagellar genes. Recent studies have found novel interactions between 
chlamydial flagellar and type III components. The flagellar ATPase FliI has been shown 
to have ATP-hydrolyzing activity and interacts in vitro with CdsL and CopN. 
Furthermore the flagellar homolog (FlhA) to the inner membrane protein CdsV can 
interact with CdsU, CdsQ, and CdsL[32]. These findings taken together with the fact that 
Chlamydia is non-motile indicate that the interaction of flagellar components with the 
type III secretion apparatus may be important in regulating its unique intracellular 
lifestyle[32,46]. 
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Table 1. Chlamydial Type III-Related Chaperones 
Chaperones Interacting partners Evidence Ref. 
Class I (Sl;:cE-like) 
SIc1 (CT043) TARP (effector) Co-immunoprecipitation and Thesis 
SIcI (homodimer) bacterial 2-hybrid (B2H). 
B2H and gel filtration 
Scc1 (CT088) Slc2 (heterodimer) 
Yeast and BacteriaI2-hybrid. [49], 
Mcsc (CT260) Capl (inc) Thesis 
CT6I8 (inc) 
Yeast 2-hybrid detected CT225 (inc) interaction between Mcsc and [49] 
Mcsc (homodimer) CapI, CT618 and CT225) 
Y2H and crosslinking 
Slc2 (CT663) Sigma 66 (RNAP) 
Scc1 ( chaperone) 
Interacts with E.coli RNAP? 
[53] 
Class II (Sl;:cD-like) Y2H 
[49] 
Scc2 (CT576,LcrHI) CopB (translocator) 
CopD (translocator) 
Scc3 (CT862, LcrH2) Co-immunoprecipitation 
[38] 
CopN (neg. regulator) 
Yeast 2-hybrid 
[49] 
CT274 
CT668 (hypothetical) 
Bacterial 2-hybrid 
CTI6I (apparatus?) [37] 
Class III (other) 
CdsE 
CdsF (needle subunit) 
CdsG (heterodimer) Yeast 2-hybrid [49] 
CdsG 
CdsF (needle subunit) 
CdsE (heterodimer) Yeast-3-hybrid [27,49] 
Yeast-2-hybrid 
CdsO (CT670) CdsP (molecular ruler) 
CdsO (homodimer) Yeast-3-hybrid 
[27,49] 
Yeast-2-hybrid 
Yeast-2-hybrid 
[33, 65] 
Bacterial-2-hybrid and Co-IP 
[35] 
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Type III secretion and Chlamydia's developmental cycle 
One common feature of all Chlamydia species is their biphasic developmental life 
cycle that imposes upon them an obligate intracellular growth restriction. A small non-
infectious but metabolically inactive EB, or elementary body, attaches to a eukaryotic cell 
membrane by reversible electrostatic-interactions with unknown host receptors. A second 
irreversible interaction occurs and entry into the host cell is guaranteed by the 
translocation of effectors by a type III secretion apparatus. Pre-formed in the EB and pre-
loaded with virulence factors, the chlamydial type III secretion apparatus translocates its 
EB-associated effectors into the host cytosol upon contact. 
Because of their complex life cycle, it has been challenging for researchers to 
stably introduce nucleic acids into the bacterium. It is not yet possible to make 
knockouts, express recombinant proteins or perform small interfering Ribonucleic Acid 
(siRNA) knockdowns in Chlamydia. For this reason, much of the characterization of 
chlamydial proteins has focused on their interactions in host cells. Thus the roles of 
chlamydial type III secreted proteins or effectors in the developmental cycle of 
Chlamydia have been a major focus of research. 
One particular EB-associated effector, TARP, the Iranslocated Actin Recruitment 
rhosphoprotein is detected in the host cytosol minutes after infection and is involved in 
hijacking host signaling molecules to the effect of inducing endocytosis of the attached 
EB[42,66-73]. Close contact with the eukaryotic cell surface allows interaction of the 
EB's disulfide-crosslinked outer membrane with host protein disulfide isomerase (PDI) 
such that the chlamydial outer membrane proteins become reduced and its uptake can 
occur. Immediately upon uptake into its endocytic vesicle, the EB's DNA starts to 
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decondense and it begins to differentiate into a large metabolically active RB or reticulate 
body. A small metabolite interrupts the interaction of the chlamydial histone-like 
proteins Hc 1 and Hc2 with chromatin and the subsequent decondensation of DNA allows 
for transcription of early genes. 
Expression of inclusion membrane proteins, IncD-G, by RBs is detected within 2 
hours of infection[74-76]. Highly divergent in sequence and function, these proteins 
share large bi-Iobal hydrophobic domains of 40-60 amino acids in length that ensure their 
localization. Secretion and outer membrane localization of these Incs is pivotal to 
forming its unique intracellular niche, the "inclusion," that diverges from the customary 
endocytic pathway. IncA, IncG and the Inc CT229 have been demonstrated to be type III 
secretion substrates by heterologous bacteria, while the mechanism of secretion of other 
Incs is unknown. Characterization ofIncA revealed a eukaryotic SNARE-like domain 
that may mediate interaction with host vesicles. Similarly IncA has been shown to 
mediate homotypic fusion of inclusion vesicles[75]. Another host mechanism that 
Chlamydia mimics to influence the trafficking of host vesicles is the recruitment of Rab 
GTPases. The Inc CT229 has been shown to interact with Rab4[77], and the C. 
pneumoniae inc Cpn0585 can interact with Rabs 1, 10 and 11 [78]. The Rab6-associating 
protein Bicaudal-l has been found localized to the inclusion as well, possibly by the 
action of an inc protein[74]. Recruitment of Rab-GTPases to the inclusion can direct 
vesicles from the golgi, multivesicular bodies, and recycling pathways to the inclusion 
where essential nutrients, amino acids and specialized lipids can be acquired. Another 
characteristic of the early inclusion is its recruitment of dynein and subsequent migration 
toward the host microtubule organizing center (MTOC)[79]. 
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A major mechanism of survival of the parasitophorous inclusion is to delay the 
host cell cycle and preventing apoptosis. The C.trachomatis IncG proteins have been 
shown to sequester the host protein 14-3-3~ and prevent phosphorylation of the pro-
apoptosis protein BAD[80, 81]. Cleavage of the cell cycle regulator cyclin B 1 was also 
detected as a consequence of chlamydial infection[82]. The secreted protein CP AF 
(Chlamydia protease-like secretion factor) has been shown to have several roles during 
infection including degrading BH3-like apoptosis proteins[83]. 
Other effectors have been shown to be involved in suppressing host inflammatory 
signaling. ChlaDubl and CT441 are able to interrupt NFkB-signalling by 
deubiquitinating IKBa and by degradation of ReIA, respectively[84, 85]. Sequestering of 
Actl by the c.pneumoniae effector CP0236 prevents it interaction with IL-17 and 
subsequent NFkB-activation[86]. CPAF has also been implicated in the degradation of 
host factors to prevent proper MHC and lipid antigen presentation[75]. 
As the inclusion becomes modified additional type III secretion needles are 
assembled and a second set of effectors is expressed. Expression of mid-cycle genes (6-
16 hours p.i.) allows for intermediate metabolism such that RBs can continue to grow and 
multiply by binary fission. Although Chlamydia do not have a peptidoglycan layer, they 
are affected by treatment with Penicillin- indicating a possible role for peptidoglycan 
during division. This theory is corroborated by the transcription of peptidoglycan 
syntheisis genes prior to cell division and the lack of an FtsZ homolog in Chlamydia 
species[23]. Possibly by a contact-dependent mechanism, newly divided RBs detach from 
the inclusion membrane and differentiate back to small infectious EBs. It has been 
proposed that as RBs divide and the inclusion size increases, individual RBs have less 
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surface contact with the inclusion membrane and detachment of the RB occurs, possibly 
by retraction of type III secretion apparatuses[75, 87, 88]. While microscopic 
observations and mathematical models support the contact-dependent model of 
detachment, the mechanism connecting detachment and differentiation remains elusive. 
Two distinct mechanisms of EB exit have been identified. Ordered 
permeabilization of the inclusion membrane, nucleus, and host cell membrane has been 
demonstrated to release EB's during cysteine protease-induced cell lysis. Extrusion, or a 
slow pinching off of the chlamydial inclusion, has also been observed at nearly the same 
frequency as cell lysis during C.trachomatis infection[89]. Future research to define any 
differences in infectivity, transmission, and pathogenesis by EB's released by lysis versus 
extrusion will be highly anticipated. 
Before secondary differentiation, however, proteins important for invasion, such 
as bacterial adhesins, components of the type III apparatus and invasion-associated 
effectors must be expressed and pre loaded for immediate translocation into the host cell. 
Gene expression of type III components have been detected from 8 hours post-infection 
onward. However, specific subsets of type III-related genes have been shown to be 
temporally regulated[90-93], indicating functions at different points in the developmental 
cycle. Evidence of transcription of type III-related genes and their temporal classes are 
compiled in Table 2. 
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Table 2. Expression of type III genes during the chlamydial developmental cycle. 
Gene Temporal class [39,91-93] Type III function 
lncG E Effector 
CT229 (lnc) E Effector 
lncA M Effector 
TARP M,VL Effector 
Slcl M Chaperone (1) 
Sccl C Chaperone (I) 
Slc2 M Chaperone (I) 
FliF (1) M Apparatus 
FliN (Q) L Apparatus 
FliA M Sigma 28 
FlhA (V) M Apparatus 
Flil (N) L ATPase 
CdsC L Apparatus 
CdsE M Apparatus 
CdsL M Apparatus 
CdsJ M Apparatus 
CdsR M,C Apparatus 
CdsS M,C Apparatus 
CdsT L,C Apparatus 
CdsU M,C Apparatus 
CdsV M,L Tip ICap 
CT274 M Chaperone (II) 
Scc2 L Chaperone (Il) 
Scc3 M Chaperone (Il) 
CopB L Translocator 
CopD L Translocator 
CopB2 M Translocator 
CopD2 M Translocator 
CopN M Neg. Regulator 
.. 
1. E= early, M=MId-cycle, L=Late-cycle, VL= Very Late C=constItUltIvely actIve. 
2. Type-III apparatus homolog to Flagellar proteins is in parenthesis. 
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Attachment 
The initial association of Chlamydia elementary bodies to the epithelial cell 
surface has been shown to involve a heparin-sensitive reversible electrostatic interaction 
with host cells. A plethora of data has been accumulated regarding the role of heparan-
sulfate like glycosaminoglycans (GAGs) in this attachment step. Early studies to 
determine possible bacterial adhesins demonstrated that infection can be limited by 
pretreatment of the bacteria or host cells with heparan-sulfate[94-1 0 1]. Coating of 
Chlamydia trachomatis and pneumonaie EBs with heparan-sulfate specific monoclonal 
antibody prevents infection[97]. Treatment of host cells or EBs with heparinase or with 
chemically-modified heparin-derivatives also prevented infection of C. trachomatis 
serovar E and L2 strains [99 , 10 1]. Several groups have attempted to determine the role 
of host cell heparan sulfate in attachment by infecting heparan-sulfate deficient mutant 
CHO cell lines. A few of these studies have indicated a reduction in attached EBs to 
these cell lines, while a more recent study has indicated that host heparan-sulfate is not 
necessary for attachment. 
Substantial evidence implicates the chlamydial antigen MOMP (major outer 
membrane protein) in the initial binding of host cells. It was shown that trypsin-mediated 
cleavage of the variable regions of MOMP inhibited C. trachomatis serovar B, but not L2 
infection[102,103]. Furthermore, in vitro treatment of host cells with MOMP-specific 
antibodies severely abrogates C. trachomatis EB binding and infection. EB-surface 
associated MOMP is linked to a glucosamine containing sulphated-polysaccharide that 
seems to be important for binding mammalian cells[96, 104-107]. N -glycanase cleavage 
of this polysaccharide prevents infection by C. trachomatis strains[1 05, 106, 108]. This 
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MOMP-associated GAG has likely complicated the interpretation of the heparin, 
heparan-sulfate, and heparinase experiments mentioned earlier. 
A second temperature-dependent binding step was discovered by infection of a 
mutant CHO cell line with Ctrachomatis L2 strain[109]. Attachment ofEBs to wild-type 
CHO cells at 4° C could be reversed by addition of heparin, but attachment at 3rC could 
not. Isolation of a mutant cell line that could be competed for binding to EBs by heparin 
at 37° C indicated a loss of the second heparin-resistant, temperature-dependent receptor. 
Many different host ligands have been proposed as this second receptor that 
remains irreversibly bound to EBs. Mannose-6-Phosphate treatment of epithelial cells 
can inhibit attachment and entry of C pneumoniae, indicating a possible role for 
Mannose-6-Phosphate receptor/Insulin Growth Factor 2 as a receptor[11 0]. Knockdown 
of host cell Platelet-derived growth factor receptor-~ (PDGFR~) with siRNA and 
treatment with PDGR~-monoclonal antibody reduce EB binding[III]. PDFR~ has also 
been indicated as an important player in Chlamydia pneumoniae infection by a recent 
systems biology study[ 112]. A recent study of the role of the cellular cystic fibrosis 
transmembrane conductance regulator (CFTR) during C trachomatis infection describes 
CFTR-dependent uptake of EBs and an increase in EB internalization by CFTR-
ectopically expressing cells[113]. 
Other bacterial adhesins besides MOMP that have been implicated in host 
receptor binding include LPS, the outer membrane complex protein OmcB, and the 
polymorphic membrane proteins Pmp6, Pmp20, and Pmp21. OmcB from Ctrachomatis 
serovars LGVl and E show GAG-dependent and independent binding to host cells, 
respectively, indicating that it may be involved in either the primary or secondary 
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attachment step[114]. C. pneumoniae Pmp proteins contain tetrapeptide repeat motifs 
that mediate binding to epithelial cells, and a recent study indicates that the presence of 
multiple Pmps have an additive effect on attachment to host cells[115]. 
A complex role for Protein Disulfide Isomerase (PDI) in attachment was also 
discovered. Reduced attachment of C. trachomatis to a CHO cell line with a mutated-
leader sequence in PDI could be restored by complementation with the full length 
PDI[116]. This requirement of PDI for attachment has been confirmed in all other 
pathogenic Chlamydia. However, it is suspected that PDI does not behave as an actual 
receptor but instead structurally associates with another host receptor to initiate 
attachment[117]. 
While enzymatic activity of host PDI is not necessary for attachment, it is an 
absolute requirement for chlamydial entry into epithelial cells. Thus, as the chlamydial 
EB is brought in close vicinity of the eukaryotic membrane by electrostatic interactions, 
another secondary host receptor in coordination with PDI irreversibly binds and reduces 
the crosslinked-outer membrane proteins and initiates uptake events such as the 
activation of the type III secretion system. Tight-binding of the type III secretion 
apparatus to the host cell membrane could indicate that the type III needle and tip 
proteins as possible secondary receptors, though further research in this area is needed to 
corroborate or disprove the role of the type III secretion apparatus in attachment. 
Despite years of research dedicated to the search for host and chlamydial 
receptors that mediate attachment, the use of a variety of host cell types and chlamydial 
species has made it difficult to determine a general mechanism for attachment. A 
compendium of this work can be found in Tables 3 and 4. 
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TABLE 3. CHLAMYDIAL ADHESINS 
Adhesin/Receptor Serovars Evidence Ref 
MOMP L2, Cps I, A 32 kDa EB protein bound Hela cell [118,119] 
exracts and heparin. 
J, L2 2. Infection could be neutralized with mAB [119] 
against 31 kDa protein. 
B,L2 3.Trypsin-mediated cleavage ofVD IV 
[102] 
prevented attachment. 
B 4. mAB against VD II and IV blocked [103, 104] 
electrostatic interactions. 
C. trach 
5.Glycan cleaved from 32 kDa protein binds 
[105] Hela cells. 
L2 
6. MOMP carbohydrate mapped to reveal N-
linked high mannose oligosaccharide. [106] 
7. Recombinant MOMP competes with EBs [120] 
C. trach for binding Helas and had reduced binding to 
heparin sulfate synthesis-deficient CHO 
cells .. 
Heparin Sulfate- I. Isolation of a heparin-sulfate-like GAG 
like GAGS C.trach from EBs recovered from GAG-deficient [121, 122] 
CHO cells. Another study was unable to 
isolate the chlamydial GAG from EBs 
cultured in a separate HS-deficient CHO cell 
line. 
L2 
2. GAG-on intracellular RBs visualized and [97] 
cleaved by lyase. 
3. Heparin-coated micro spheres were taken [98] up similarly to EBs. 
4. Desulfation of L2 or E EBs by sodium 
LGV,E chorate treatment did not reduce infectivity. [123] 
Ctr, Cpn 
5. Treatment ofCpneumo strains and C.tr E 
EBs with heparin derivatives or heparatinase [101 ] 
inhibit infedtion 
OmcB I. OmcB was identified as binding heparin. 
LGV,E The Binding region was mapped to a 20-mer [124] 
peptide whose addition could out-compete 
binding by OmcB. 
Cpneumo., 2. Addition of recombinant OmcB from 
L2,E LGVI but not E prevents EBs from binding 
[114] 
host cells. Attachment of LGV I rOmcB but 
not E was abrogated in the presence of 
heparin. 
3. Expression ofC.pneumo OmcB on Yeast 
[125] 
Ctr,Cpn,Cps was sufficient for binding to epithelial cells 
and addition of heparin prevented this 
binding. Addition of OmcB recombinant 
22 
protein or monoclonal antibody prevents 
C.pneumo EB attachment to host cell. 
LPS E,LGV 
I.Chalmydia LPS immunoprecipitates with 
[113 ] CFTR. 
1. Recombinant expression of Pmp6, 20, or [115] 
21 on yeast cells mediates adhesion to 
Pmps Cpn, Ll E epithelial cells. Treatment of host cells with 
recombinant Pmps or mAb against these 
proteins prevents C pneumo infection. 
Binding can be attributed to the tetrapeptide 
motifs in these proteins. 
TABLE 4. HOST CELL RECEPTORS 
Receptor Cell types Evidence Ref 
PDGFRp S2, Hela I. Treatment of host cells with PDGFR~ siRNA or [111 ] 
mAb reduces C.trachomatis L2 binding. 
2. Uptake of C.trachomatis EBs is blocked by [113 ] 
CFTR Hela CFTR mAbs and by treatment with CFTR 
CFTR-/- mice inhibitors. Also there was a reduction in EB 
uptake by CFTR knockout mice. CFTR can also 
be co-immunoprecipitated with LPS. 
M6P receptor Hela I. Mannose-binding protein interacts with MOMP [126] 
and prevents interacation of C.trachomatis with 
host cells. 
HMEC-l 2. Addition ofM6PR or M6P analog prevents [110] 
attachment ofC.pneumo but not C.trachomatis 
strains to endothelial cells. 
PDI CHO-6 1. The CHO-6 cell line is mutant for PDI and is [116] resistant to attachment that could be recovered 
with FL PDI. 
2. siRNA knockdown of PDr prevents infection. 
CHO-6, Hela Chlamydia does not bind directly to PDI-gpi. [117] 
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TABLE 4. HOST CELL RECEPTORS (cont.) 
Receptor Cell types Evidence Ref 
Heparin- Hela I. 32 kDa and IS kDa EB surface proteins are [118] 
sulfate prevented from binding host cell by heparin. 
Hela, CH0761 
2. Infection inhibited by adding heparin-sulfate [121, 127] receptor or heparatinase. 
L929, Hela 3. Heparatinase treatment of LGV and trachoma 
[127] 
EBs prevented attachment. 
Hela, L929 4. Heparin inhibition of LGV and trachoma biovar [94] 
infections was rescued by competition with a 
sulphated decasaccharide. 
CHO 
5. A heparin sulfate synthesis-deficient CHO cell 
[120] line had reduced EB infectivity. A separate HS-
deficient CHO cell line was resisitant LGV but not 
E infection. 
L929,Hela 6. Attachment of LGV EBs to was completely [107,122] 
inhibited by pretreatment with heparin or 
CHO 
heparatinase. 
[107,128] 7. Attachment of Trachoma biovar EBs was only 
partially inhibted by heparin or heparatinase 
pretreatment. 
Hela, McCoy S. Serovar E attachment not inhibited [128] 
by heparin or heparan sulfate, but L2 was 
Hela, McCoy 
completely inhibited. 
[95] 9. Heparatinase blocked C.psittaci EB attachment 
at 4° and 37° while heparin blocked attachment at 
4°. 
Hela 10. Inhibition ofC.trachomatis infectivity by [96] 
sulphated polymers or polysaccharides in vitro (eel 
culture) but not in vivo (mouse model) 
Hela? II. Heparin sulfate mAb binds to C. trach and C.pn 
[97] EB surface and neutralizes infectivity. 
Hela, CHO 12. Heparatinase treatment of host cells prevented 
L2 infection and the HS-synthesis deficient CHO [99] 
cell line was less sensitive to infection. 
McCoy, Hela 13. Desulfation of host cells by sodium chlorate 
[123] inhibited L2 but not E infection. 
CHO 14. The HS mutant cell line CHO-IS.4 was 
infected equally by L2 and D and was comparable [100] 
to infection ofWT CHO cells. 
HL I5.Treatment of host cells with heparinase and [101 ] 
heparin derivatives prevented infection by C.pn 
strains and C.tr E. 
CHO 16. OmcB-expressing yeast from Cpn and C.tr-L I 
[125] 
were unable to bind heparatinase treated or GAG-
deficient CHO cells. 
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Entry 
Following attachment of EBs, uptake by the endocytic pathway is induced by 
chlamydial factors. Uptake of chlamydial EBs by epithelial cells is associated with the 
recruitment of actin and tyrosine phosphorylation of proteins at the site of entry for 
Ctrachomatis[42, 73, 129, 130]. This actin recruitment is dependent on the activation of 
the small Rho GTPase Rac in Ctrachomatis infection, while both Cdc42 and Rac 
activation are important for C caviae entry[72, 131]. A tyrosine-phosphorylated protein 
associated with actin recruitment has been identified to be the chlamydial type III 
translocated protein TARP. Ctrachomatis LGV TARP contains six tyrosine-rich repeat 
domains that can be tyrosine phosphorylated by several host kinases containing the Src-
homology 2 -domain (SH2). The SH2-containing kinases Src, Yes, Fyn, Syk, and Abl 
are all able to phosphorylate tyrosine residues ofC.trachomatis TARP[66, 68,132]. The 
observation that individual knockdown of anyone of these kinases does not completely 
abrogate tyrosine phosphorylation reinforces the importance of T ARP phosphorylation 
for efficient manipulation of host signaling cascades and actin remodeling. Type III 
effector-induced actin polymerization and cytoskeletal rearrangement has been 
extensively studied in other bacteria pathogens. Enteropathogenic E. coli stimulates acitn-
pedestal formation through the type III translocation ofTir (translocated intimin receptor) 
into host cells where it is tyrosine-phosphorylated and associated with Arp2/3 
recruitment[133, 134]. The SPI-l (Salmonella Pathogenicity Island-I) type III secretion 
system induces bacterial uptake by translocation of effectors that induce membrane 
ruffling and Rho GTPase activation[135]. 
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Tyrosine phosphorylated residues in C trachomatis T ARP are able to recruit the 
guanine nucleotide exchange factors Sos-I and Vav-2[67, 68]. A complex ofSos-I, 
Eps8, and Abi-I or Vav-2 with PIP3 (phospho-inositoI3,4,5-P3) have been shown to 
activate Rae in a phosphotyrosine dependent manner[67]. Rae-dependent recruitment of 
actin has been shown to involve Abi-I and WAVE-2 dependent formation of the actin-
nucleating Arp 2/3 complex[69]. While Ctrachomatis L2 and D TARPs contain 6 and 3 
tyrosine-rich repeats (TRR), respectively, Ccaviae, Cpneumoniae, and Cpsittaci do not 
contain TRRs. All chlamydial T ARPs do contain proline-rich domains that induce T ARP 
aggregation and C-terminal WH2-like domains that are capable of nucleating actin [70]. 
It has been proposed that the WH2 domains on T ARP may contribute to the further 
polymerization of the short actin filaments already induced by the Arp2/3 complex[69]. 
A recent protein microarray indicated the interaction of an SH2-containing 
adaptor protein SHC 1 with TARP derived phosphopeptides. Infection of SHC 1 
knockdown cells sensitized Chlamydia to TNF-induced apoptosis, and detection of 
SHC I-regulated genes included those involved in apoptosis and growth[136]. Taken 
together, previous findings clearly indicate that T ARP plays a critical role in the entry 
and survival of Chlamydia trachomatis in host cells, and thus its translocation through the 
bacterial type III secretion apparatus into mammalian cells must be absolutely efficient to 
ensure survival of the organism. 
Besides TARP, the EB-associated type III effectors CTI66 and CT694 have been 
reported to be associated with entry-related signaling. As a homolog to the chlostridial 
glucosylating toxins, the mono-glucosylation and subsequent deactivation of Rac by 
CTI66 has been demonstrated in Hela cells. Since this effector is translocated into host 
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cells shortly after infection it is likely that it provides a balance to the actin remodeling 
induced by T ARP during C. trachomatis entry[ 13 7]. The association of CT694 with the 
host protein AHNAK to alter stress fibers may also be important for invasion.[138] 
Tyrosine-phosphorylation of the host protein Ezrin has also been discovered as a 
direct result of C. trachomatis infection of epithelial cells[ 13 9]. Like T ARP, the tyrosine-
phosphorylation of Ezrin upon infection led to its association with actin, specifically in 
microvilli.[140] The specific kinase(s) involved in Ezrin tyrosine phosphorylation during 
Chlamydia infection have not been determined, but previous studies have demonstrated 
that this event can be a direct result of host receptor binding and activation[141]. 
Chlamydial attachment to and subsequent phosphorylation of PDGFR~ results in 
phosphorylation of W A VE2, Cortactin, and the guanine-exchange factor Vav2 [111]. 
Phosphorylation and subsequent activation of these molecules is associated with actin-
remodeling events. It is clear that multiple and redundant signaling pathways are 
hijacked by Chlamydia species to ensure efficient uptake of the organism. Upon cell 
contact, immediate secretion of chlamydial factors such as T ARP into the host cytosol is 
critical for initiating actin-cytoskeletal remodeling and subsequent endocytosis of the EB. 
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HYPOTHESIS 
I hypothesize that a chlamydial factor is responsible for the efficient association 
of T ARP with the type III secretion apparatus and its ensuing translocation into the host 
cell cytosol. I propose that the Chlamydia trachomatis Class I type III secretion 
chaperone SIc 1 interacts with T ARP and is responsible for its efficient translocation 
through the type III apparatus. 
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CHAPTER II. 
MATERIALS AND METHODS 
Bacterial strains and cell culture. 
Chemically competent Top10 and BL21star E. coli strains from Invitrogen were used for 
plasmid propagation and protein expression, respectively. The adenylate cyclase (cya) 
deficient DHM1 E. coli strains were grown at 30° C on indicator plates (LB + 40 flg/ml 
X-gal + 1mM IPTG or McConkey + 1 % maltose) for 48 hours or in Luria-Bertani broth 
(LB) at 37°C. All other E. coli strains were grown at 37° C in LB broth or agar plates. 
The Yersinia enterocolitica WT strain MRS40 or L1 Y scN E40(PMSI41) strain were 
grown in LB or Brain-Heart-Infusion (BHI) broth at 26° C. Media was supplemented 
with 100 flg/ml carbenicillin (carb), 60 flg/ml kanamycin (kan), 12.5 flg/ml tetracycline 
(tet), or 35 flg/ml Nalidixic Acid, when appropriate. The wild-type EPEC serotype 
0127:H6 strain E234/69 and the cesT knockout strain were obtained from Gadi Frankel's 
lab and grown in LB broth. The Salmonella eneterica typhimurium strain 12023s was 
obtained from David Holden's lab and grown in LB broth. Hela cells were cultivated at 
37° C with 5% CO2 in DMEM supplementedwith10% FBS and 2 mM L-glutamine. 
Plasmid construction. 
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Slc l, Scc1, Mcsc, Slc2, and the N -terminal 600 nucleotides of TARP were amplified 
from Chlamydia trachomatis genomic DNA (gDNA), CesT and the N-terminal 600 nt of 
Tir from enteropathogenic E. coli gDNA, and Y opH from Yenterocolitica MRS40 
gDNA by the polymerase chain reaction (PCR) using the primers listed in Table 5. 
Cloning into pETlOl, pET200, pBAD-TOPO and pENTR-D/SD-TOPO utilized the 
endogenous topoisomerase activity of Invitrogen directional cloning vectors. The PCR 
fragments CACC-CT043-FLAG-stop (and CACC-CT663-FLAG-stop were cloned into 
pETlOlID-TOPO, resulting in the plasmids pETlOl-Slc1-FLAG and pETlOl-Slc2-
FLAG, respectively. The PCR fragment CACC-TARp l -200 was cloned into pET200/D-
TOPO, resulting in the plasmid pET200-TARp l -200 . All of the constructed plasmids were 
transformed into TopiO cells, recovered in SOC medium for one hour at 37° C, and 
plated on LB agar supplemented with carb, kan or both. The resulting colonies were 
restreaked and grown overnight. Presence of the correct plasmid inserts was confirmed 
by colony PCR and sequencing. The PCR fragments CACC-CT043 and CACC-CT088-
FLAG were cloned into pENTRISD/D-TOPO, resulting in the plasmids pENTR-Slci and 
pENTR-Scci-FLAG, respectively. These new entry vectors were recombined with pET-
56-DEST using LR recombinase II reaction mix (Invitrogen), transformed into Top 1 0, 
and selected for on LB+carb agar overnight. The resulting colonies were restreaked on 
carb plates and grown overnight. The presence of the correct plasmids was determined 
by colony PCR and sequencing. Plasmid DNA was purified from the TopiO genetically 
modified strains by using Qiaprep Spin Miniprep Kit.(Qiagen). The BL2I star expression 
strain was singly or co-transformed with pET200-TARP200, pETlOI-SlcI, pETlOI-Slc2, 
and pET56-Scc I-FLAG. For the expression of chlamydial proteins in Yersinia, I digested 
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Slc2 and Scc1 from petl0l-Slc2 and petlO1-Scc1 with XbaI and ScaI-HF (NEB). These 
digested inserts were then ligated into the XbaI and Seal sites of pBAD 18 (American 
Tissue Culture Collection). Mcsc and SIc1 were cloned into the pBAD-TOPO vector. 
SLIM PCR was used to add a KpnI sited downstream of T ARP in the vector pet200-
TARp l -200 to form pet200_TARp l -200 -kpnI. This vector was then digested with NdeI and 
KpnI and the resulting NdeI-TARp l -200 -KpnI fragment was cloned into these sites in 
pCX340. For co-expression in the bacterial2-hybrid system, all of the PCR inserts were 
generated to have flanking XbaI and KpnI sites and were cloned into the same sites in 
pUT18C and/or pKT25 prior to co-electroporation into DHMI E. coli. 
Protein expression, lysate preparation, and protein purification. 
Overnight cultures of BL21 star strains were diluted 1 :20 in LB + antibiotic, and grown 
to OD600 of 0.6. Expression of recombinant proteins was induced by addition of 0.5 mM 
isopropyl-P-D thiogalactopyranoside (lPTG) and incubated for 3 hours with shaking. 
Bacteria were centrifuged at 8000g for 20 minutes, and the pellet was resuspended in 
III 0 culture volume of lysis buffer (50mM NaH2P04, 300mM NaCI, 0.05% TIen, 0.1 
mg/ml Dnase I, 1 mg/mllysozyme, Halt Protease Inhibitor Cocktail (Pierce)). For 
preparation of lysates that were added to NiNta Magnetic Beads, 25 mM imidazole was 
added to the lysis buffer. Bacteria were incubated in lysis buffer for 30 minutes at room 
temperature, sonicated to shear DNA, and stored at -80°C. Purifications of Slcl-FLAG 
and His6- TARp l -200 for use in crosslinking and gel filtration experiments were 
performed using M2-Anti-FLAG agarose (Sigma) and Ni-Nta Agarose (Qiagen), 
respecitively. Lysozyme was left out of the lysis buffer and the french press was used to 
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release soluble proteins from these lysates prior to clearing by centrifugation at 15,000 g 
for 30 minutes. Purification fractions were run on 12% SDS-PAGE gels and proteins 
were stained with a 0.2% Coomassie Blue R250 solution. 
Coimmunoprecipitation assays and immunodetection. 
Bacterial expression lysates were thawed and partially cleared by centrifugation at 4000g 
for 15 minutes prior to addition to M2 Anti-FLAG Agarose (Sigma) or NiNta Magnetic 
Beads (Qiagen). 30 mM imidazole was added to 500 ).1llysates prior to incubation with 
the magnetic beads on an end-over-end rotator overnight at 4°C. The flow-through 
fraction or supernatant was separated from the beads with a magnetic separator, and the 
beads were washed five times with NiNta Native Wash Buffer (50 mM Na2HP04, 300 
mM NaCl, 20 mM imidazole, 0.05% TIen 20, PH 8.0). The first (WI) and fifth (FW) 
wash fractions were kept for analysis, and the native protein complexes were eluted from 
the beads by incubation with 100 ).11 NiNta Native Elution Buffer (50 mM Na2HP04, 300 
mM NaCl, 300 mM imidazole, 0.05% Tlen 20, pH 8.0) at 4°C for 4 hours. For each 
coimmunoprecipitation experiment with M2 Anti-FLAG agarose, 1 mlofbacteriallysate 
was added to 100 ).11 of packed agarose resin and incubated on an end -over-end rotator at 
4°C overnight. The flow-through fractions were collected by centrifugation at 3000 g for 
1 minute, and the resin was washed five times with tris-buffered saline (TBS, prior to 
elution of the native protein complexes by incubation with 100 ).11 of 200 ng/ml 3XFLAG 
peptide (Sigma) in TBS at 4°C for 4 hours-overnight. Immunoprecipitations of S-tagged 
proteins were done as per the S-tag ReK purification kit manual. (Novagen). 
Immunoprecipitation fractions were incubated 1: 1 with Laemmli sample buffer (Biorad) 
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+ 0.5 % ~-mercaptoethanol at 95°C for 10 minutes prior to separation by SDS-PAGE. 
Proteins were transferred to polyvinylidine fluoride (PVDF) membrane and detected by 
Western blot probed with 6XHIS, DDDDK, and S-tag specific antibodies from Abcam 
(cat#: ab18588, ab21536, ab18184, ab49763, abI187). HRP-conjugated goat-anti-mouse 
(Millipore 12-349) or HRP-goat-anti-rabbit (Pierce #185415) were used as secondary 
antibodies when necessary, followed by development with Millipore Immobilin Western 
Substrate. 
~-galactosidase assay. 
A modified Miller assay was followed[142]. Briefly, co-expressing DHMI strains were 
grown overnight in LB+antibiotic at 37°C followed by a 1 :50 subculture and growth in 
fresh LB+antibiotic to an OD600 of 0.5-0.8. The OD600 of the culture was recoded and 
20 ul of culture was added to 80 ul of permeabilization buffer (20 mM KCl, 2 mM 
MgS04, 0.8 mg/mL CTAB (hexadecyltrimethylammonium bromide), 0.4 mg/mL sodium 
deoxycholate, 5.4 llL/mL beta-mercaptoethanol) and incubated at 30° C for 30 minutes. 
The time was recorded as 600 ul of pre-warmed substrate solution (60 mM Na2HP04, 40 
mM NaH2P04, 1 mg/mL o-nitrophenyl-~-D-Galactoside (ONPG), 2.7 llL/mL ~­
mercaptoethanol) was added to each permeabilized sample and incubated at 30°C. Upon 
developing a yellow color, the samples were stopped with 700 ul of 1 M Sodium 
Carbonate (Na2C03) and the stop time was noted. 
Co localization assay. 
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The open reading frames of SIc 1 and Slc2 were cloned into pENTR/D-TOPO and 
recombined into pDest-N-mcherry by the LR recombinase reaction as described by the 
Gateway expression manual. (Invitrogen) Mcherry-Slc1, Mcherry-Slc2, or Mcherry gus 
were co-transfected with full length C. caviae GFP-TARP into Cos-7 cells with Fugene 6 
Transfection Reagent as indicated in the Fugene 6 Technical Bulletin. (Roche) 
Transfected constructs were expressed for 24 hrs before the cells were fixed with 4% 
Paraformaldehyde on glass coverslips and analyzed with an Olympus Fluoview 500 
Laser Scanning Microscope. 
Secretion Assay. 
Overnight cultures of Y.enterocolitica strains containing pcx340 and pBAD vectors were 
diluted to an OD600 of 0.2 in 5 ml ofBHI + 2.5 mM CaCl2 (represses Yop production) 
or BHI + 0.4% glucose + 5 mM EGTA + 20 mM MgCl2 (induces Yop production) for 2 
hours at 26° C. Expression of recombinant proteins were induced with the addition of 1 
mM IPTG and 13 mM L-Arabinose, upon shifting to 37°C (type III secretion-inducing 
conditions). Secretion was induced for 4 hours prior to centrifugation at 3000g for 20 
min. The top 9 ml of the supernatant were removed and respun at 12000g for 30 minutes 
at 4°C. This supernatant was further cleared with a 0.45 uM filter and proteins were 
precipitated with ice-cold 10% TCA. Precipitated proteins were pelleted, washed twice 
with ice-cold acetone, and dried prior to resuspension in a proportional volume of Lysis 
buffer B (0.1 M Tris-Hcl, 0.1 M NaH2P04, 300 mM NaCI, 6 M Urea) to cell pellet. 
Lysates were treated 1: 1 with Laemmli + 5% ~ME and heated to 95° C for 15 minutes 
priort to separation on a 12% SDS-PAGE gel. Protein concentration in the whole-cell 
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pellet was determined by bicinchoninic acid assay (BCA) and the protein in whole-cell 
pellets was normalized to 1 mg/ml in Lysis buffer B. 
Yersinia enterocolitica Translocation Assay. 
Hela cells were plated in black, flat, glass-bottomed 96-Ill plates at a density of 1 X 104 
cells per III and allold to grow for 24 hours prior to infection. One day prior to infection 
TEM-1 fusion protein (pcx340) and pBAD18-chaperone expressing Y enterocolitica 
strains were inoculated into 3 ml of BHI broth + tet ± carb and grown at 26° C overnight. 
The following day, the cultures were diluted 1 :20 in BHI + antibiotics and grown at 26 C 
for 1 hr. 1 mM IPTG and 13 mM L-Arabinose were added to the cultures and were 
grown for 2 more hours at 26° C. Monolayers were washed twice with HBSS, and 
infected with Yenterocolitica at an MOl of 10. After 1 hr of infection at 37°C, the 
monolayer was washed twice and fresh DMEM was added. The infection progressed for 
2 more hours at 37° C in 5% CO2 . Infected cells were washed 3 times with HBSS and 
topped with lOOul ofHBSS. The 1xCCF2/AM substrate was prepared as per the 
manufacturer's manual (Invitrogen) and 20 ul was added to each Ill. Infected cells were 
incubated at RT for 1.5 hrs in the dark prior to fluorescence detection at 450 and 520 nm 
with a fluorimeter (excitation at 410 nm). 
Enterropathogenic E.coli and Salmonella typhiumurium translocation assays. 
Enterropathogenic E.coli or Salmonella typhimurium was inoculated into LB broth + 
tetracycline and chloramphenicol and allowed to grow at 37° C overnight. Cultures were 
diluted 1 :33 in fresh LB broth + antibiotics and allowed to grow to mid-log phase at 37° 
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C (shaking for Salmonella, no shaking for EPEC). Bacteria were pelleted, washed and 
resuspended in PBS and added to 80% confluent HeLa cell mono layers at a multiplicity 
of infection (MOl) of 50. For the EPEC and SPl-1 assays, the mono layers were infected 
for 2 hours prior to the washing and CCF2/AM steps (see above), while the Salmonella 
were allowed to infect cells for 9 hours in the SPI-2 assay at an MOl of 10. 
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CHAPTER III 
IDENTIFYING INTERACTIONS BETWEEN TARP AND TYPE III 
CHAPERONES FROM CHLAMYDIA TRACHOMA TIS 
Since TARP translocation is a critical event that ensures the uptake and survival 
of Chlamydia, I sought to identify any type III secretion chaperones that may facilitate its 
translocation. From earlier in silica studies, I knew that three such type III class I 
(effector) chaperones were predicted in C. trachomatis genome. I manually aligned the 
predicted secondary structures of the open reading frames CT043, CT088, and CT663 
with known class I effector chaperones from other pathogenic bacteria (Figure 2). In this 
figure I annotated the aforementioned chaperones as SIc1, Scc1, and Slc2. Previous 
studies had coined Scc 1 (Specific Chlamydial Chaperone 1) for CT088 [41]. Throughout 
this study I refer to CT043 and CT663 as SIcI and SIc2 for furcE-L.ike Chaperone 1 and 
2, respectively. 
The predicted chlamydial chaperones shared the a-~-~-~-a-~-~ secondary 
structure characteristic of type III effector chaperones. Interestingly, all three putative 
chaperones were reported to be present in the elementary body proteome, [143-146] 
suggesting that these chaperones may function in the translocation of EB-associated 
effectors. These findings convinced us to test these putative chlamydial chaperones for 
their ability to interact with the invasion-associated effector T ARP. 
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Figure 2. Secondary structure alignment of type III chaperones. 
Three C trachomatis proteins share predicted secondary structural features characteristic 
of known type III export chaperones. Primary amino acid sequence alignment of known 
type III export chaperones CesT (EPEC), SycE (Yersinia enterocolitica) and SicP 
(Salmonella enterica serovar typhimurium) with the putative export chaperones Slcl 
(CT043), Slc2 (CT663) and Scc1 (CT088) of Ctrachomatis. Secondary structure was 
predicted using Jpred and sequences aligned manually to according to the a-~-~-~-a-~ ­
~-a signature characteristic of some type III export chaperones. Residues predicted to 
form a-helices and ~-strands are highlighted dark grey and light grey, respectively. 
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Interaction of the N-terminal200 amino acids ofTARP with the chaperone SIc1. 
Since chaperones typically bind their effectors within the N-terminal 30-150 
amino acids, I chose to test the N -terminal 200 amino acids of T ARP for binding by the 
three putative chlamydial chaperones Slc 1, Slc2, and Sccl. I utilized two independent 
approaches - co-immunoprecipitation and the bacterial two-hybrid system to confirm a 
chaperone-binding partner for TARP. Both of these approaches alloId us to identify 
interactions between native recombinant proteins and have both been used previously to 
identify type III chaperone:effector interactions[38, 147]. Co-immunoprecipitation is a 
directed blunt-force approach for identifying in vitro interactions, while the bacterial two-
hybrid assay allows for real-time interaction of expressed proteins and is conducive to 
quantitative analysis. 
For bacterial expression in the co-immunoprecipitation assays, I cloned the N-
terminal 200 amino acids of L2 TARP into pET200 (Figure 3) and expressed the 
recombinant N-terminus ofTARP with an N-terminal6XHIS tag (HIS6_TARpl-200). 
Each of the predicted chlamydial chaperones were cloned into pETl 01 (Figure 5) and 
expressed to have C-terminal FLAG tags. A stop codon was included after the FLAG tag 
to exclude the vector-encoded 6XHIS tag from the chaperone open reading frame. 
Expression of recombinant T ARP and chaperones such that they had different tags allold 
us to purify interacting proteins using two different immobilization approaches: HIS6-
TARpl-200 with Ni-Nta magnetic beads or chaperone-FLAG with M2 Anti-FLAG 
agarose. The separate recombinant tags for T ARP and chaperones were also important 
for immunodetection by Western blot analysis. 
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The open reading frames of the N-terminal200 amino acids ofTARP were 
amplified from Ctrachomatis Serovar L2, Mouse pneumonitis, Cpneumoniae, and 
C caviae by PCR. (Fig 3) SIc I, Sccl, and Slc2 were amplified from C trachomatis 
serovar L2 genomic DNA by PCR. (Fig 5) The purified PCR products were cloned into 
Invitrogen's directional cloning vectors (pET200 and pETIOI) by using the energy stored 
in a bond between the 3' phosphate of the linear vector and Vaccinia virus topoisomerase 
I to join the 5' CACC overhang from PCR products with the GTGG overhang of the 
. linear vector. This allows for directional blunt-end annealing of the PCR products to the 
linear vectors without any digestion and ligation steps. Transformation of these cloned 
vectors into chemically competent Top IO cells gave a high yield on antibiotic-selective 
plates, and colonies were checked for correct inserts by colony PCR. (Figures 4 and 6) 
Plasmid DNA from each positive clone was confirmed for the correct inserts by 
sequencing (Genomic Core-Baxter II, University of Louisville). 
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Figure 3. Amplification of T ARP inserts for cloning into pET200. 
(Top) Vector diagram of the pET200 directional topo cloning vector from Invitrogen. 
(Bottom) PCR-amplified inserts of the N-terminal200 amino acids ofTARP from 
different Chlamydial species are displayed on a 1 % agarose gel. 
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Fig 4. Colony PCR of transformants of pET200- T ARP 1-200. 
Colony PCR was performed on kanamycin-selected transformants and the 1.2% agarose 
gels displayed here indicate the foresence of the T ARP200aa inserts for each Chlamydia I 
species in the pET200-TARp l-2 0 vector. 
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Figure S. Amplification of chaperone inserts for cloning into pETIOl. 
(Top) Vector diagram of the pETlOl rectional topo cloning vector from Invitrogen. 
(Bottom) PeR-amplified inserts of the putative type III secretion chaperones from C. 
trachomatis serovar L2 are displayed on a 1 % agarose gel. 
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Fig 6. Colony PCR of transformants of pETIOl-chaperones. 
Colony PCR was performed on kanamycin-selected transformants and the 1.2% agarose 
gels displayed here indicate the presence of Ctrachomatis serovar L2 CT663 , CT088, 
and CT043 inse11s in the pETI0l vector. 
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Cleared BL21 star E.coli lysates containing HIS6-TARpl-200, chaperone-FLAG, or 
a mixture of the 2 lysates were incubated with M2 Anti-FLAG agarose for 4 hours at 4°C 
to allow protein complexes to form and become immobilized on the agarose. After 5 
wash steps to remove any non-specific proteins, I eluted the protein complexes with 250 
mM 125 Ilg/mI3XFLAG peptide. The specific retention ofTARP by the chaperones was 
monitored in the flow-through, wash, and elution fractions by Western blot analysis 
(Figure 7). 
The M2 Anti-FLAG beads retained HIS6-TARpl-200 in the presence of 
recombinant SIc1, but not Slc2 or Scc1 indicating a specific interaction with SIc 1, but not 
the other chaperones. HIS6-T ARP 1-200 was present in all of the co-immunoprecipitation 
samples as evidenced by its presence in the flow-through fraction, therefore the lack of 
interaction with SIc2 and Scc 1 was not due to an absence of T ARP in the combined 
lysates. I can also eliminate excess protein forcing an interaction because the low level of 
Imidazole (20 mM) in the wash buffer in combination with the multiple wash steps 
should eliminate any non-specific interactions. One minor caveat of this approach is that 
mixing of separately expressed, prefolded proteins may not be ideal for studying their 
native interaction. 
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Figure 7. Pull-down of TARP by chlamydial chaperones from singly expressed 
Iysates. Irnmunoblots of flow-through (FT), first wash (WI), final wash (FW), and 
elution (E) fractions following M2 Anti-FLAG co-immunoprecipitation ofSlci-FLAG, 
Slc2-FLAG or Scc1-FLAG in the presence or absence of His6-TARP'-200 from laboratory 
Ecoli lysates following individual expression were detected using anti-FLAG and anti-
His6 antibodies, respectively. 
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To confirm the observed SIcl binding to HIS6_TARPI-200, I performed the reverse 
co-immunoprecipitation reaction in which TARP was immobilized to Ni-Nta magnetic 
beads and monitored the different fractions for SIcI-FLAG content by Western blot 
(Figure 8). In this experiment, lysate from a BL21 star E. coli strain that co-expresses 
SIc1-FLAG and HIS6_TARpl-200 was incubated with Ni-Nta magnetic beads. Fractions 
were processed and detected as stated previously. As expected, I found that the Ni-Nta 
magnetic beads when co-expressed with HIS6-TARPI-200 retained high levels of 
recombinant SIc 1, but none was retained in its absence. 
In addition, I tested whether co-expression of Scc1 or Slc2 with TARP enhanced 
their interaction (data not shown) and I was unable to detect any Scc1 or SIc2 in the 
elution fraction, giving confirmation that T ARP interacts specifically with the putative 
chaperone SIc 1. I also observed a relatively higher level of TARP retained in the reverse 
co-immunoprecipitation experiment that utilized lysates from E. coli co-expressing both 
TARP and Sicl. 
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Figure 8. Pulldown of chaperones by T ARP following coexpression 
Immunoblots of flow-through (FT), final wash (FW), and elution (E) fractions following 
Ni-Nta immunoprecipitation of His6_TARPI-200 from laboratory Ecoli lysates following 
expression ofTARpl-200-His6 or SIc1-FLAG alone, or after co-expression as indicated_ 
SIc1-FLAG and TARPI-200_His6 were detected using anti-FLAG and anti-His6, 
respectively_ 
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To confirm independently the Slcl-TARP interaction demonstrated by co-
immunoprecipitation, the bacterial two-hybrid technique was used[148, 149]. The N-
terminus of chlamydial TARP was fused to the C-terminus of the Bordatella pertussis 
adenylate cyclase (cya) 18-fragment (CyaJ8-TARP) in the vector pUT18C (Fig 9). Each 
of the chlamydial chaperones, including the recently described Mcsc, which has a 
chaperone-like activity, was cloned into the vector pKT25 (Figure 9) and expressed as C-
terminal fusions to the 25 fragment of cya (Cya25-SIc1, Cya25-Scc1, Cya25-Mcsc, and 
Cya25-Slc2). The TARP and chaperone inserts were amplified by PCR and ligated into 
the XbaI and Kpnl sites of the pUT18C and pKT25 (Figures 10 and 11) vectors, 
respectively. The ligated vectors were transformed into BL21 star and transformants were 
checked for the correct inserts by colony PCR followed by DNA sequencing (Fig 10 and 
11). 
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Figure 9. Diagram of the pUT18C and pKT25 ~-Iactamase fusion vectors. 
(Top) Diagram of the pUT18C vector. (Bottom) Diagram of the pKT25 vector. 
Colony PCRs of ampicillin-selected pUT 18C-T ARPOO transform ants separated on a 1 % 
Agarose gel. 
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Figure 10. Cloning of the N-terminus ofTARP into pUT18C. 
(Top) PCR of the TARP200aa insert with XbaI and KpnI sites run out on a 1.2% 
Agarose gel. (Bottom) Colony PCR of the ampicillin-selected pUT18C-T ARP200aa 
transformants run out on a 1.2 % Agarose gel. 
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Figure 11. Confirmation of pKT25-chaperone transformants. 
Kanamycin-selected pKT25 transformants were checked for their chlamydial chaperone 
inserts. Colony PCR for SIcI (Top left), Mcsc (Top right), Scc1 (Bottom left) and CT663 
(Bottom right) were separated on 1.2% agarose gels. 
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Figure 12. Diagram of the E.coli 2-hybrid system. 
Co-expression of the TI8 and T25 fusion proteins in adenylate cyclase-deficient (cya) 
E.coli yields two scenarios: 1. (Left) The fusion proteins do not interact and the cya toxin 
is not reconstituted. No cylic-AMP (cAMP) is formed and the lactose and maltose 
operons are not transcribed. 2. (Right) The fusion proteins interact, bringing together the 
T18 and T25 fragments and reconstituting the toxin. Cya mediates the formation of 
cAMP, and it fmiher interacts with the catabolite activator protein (CAP) to co-activate 
transcription of lactose and maltose operons. 
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These fusion vectors were then co-expressed in the cya deficient E. coli strain 
DHM1. In this bacterial2-hybrid assay, interaction between fusion proteins results in the 
reconstitution of the adenyl ate cylcase (cya) enzymatic domain and catalyzes the 
conversion of ATP to (cAMP). Available cAMP, along with the catabolite activator 
protein (CAP) co-activates the maltose and lactose operons (Fig 12). Activation of the 
lactose operon leads to Beta-galactosidase (p-gal) production, which cleaves the 
colorimetric substrate X-gal to yield blue colonies on LB + x-gal + IPTG plates. IPTG 
was included in the plates to relieve repression of the endogenous lactose operon by lac!. 
Activation of the maltose operon in colonies growing on McConkey + 1 % maltose plates 
leads to a color change of the phenol red in the agar to fuchsia in the presence of acidic 
maltose degradation products[148, 149]. This bacterial2-hybrid system gives quick, 
reproducible results on indicator plates, and protein-protein interactions can be quantified 
in a ~-galactosidase reporter assay. I was able to detect an interaction between Cyal8-
TARP and Cya2s-SIc1 by blue and fuchsia colonies on X-gal and McConkey plates, 
respectively (Figure 13). Bacteria co-expressing Cya 18-TARP and Cya25-Scc 1, Cya2S-
Mcsc, or Cya25-Slc2 were similar to the negative control, and did not produce an obvious 
color change to blue or fuchsia on indicator media. 
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Figure 13. Bacterial2-hybrid interactions between TARP and chaperones on 
indicator plates. 
LB + X-gal + IPTG (left) or McConkey + maltose (right) agarose plates indicate 
interaction between co-expressed Cya15 or Cya18 fused chlamydial chaperones in the 
cya deficient E. coli strain DHM 1. Upregulation of the lactose and maltose operons 
results from fusion-protein interaction and is indicated by blue or fuchsia bacteria. These 
results are representative of multiple trials. 
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The results obtained from colonies on indicator plates were confirmed and 
quantified by monitoring p-galactosidase activity as previously described. Briefly, I 
permeabilized co-expressing DHMI strains and measured the p-gal-mediated conversion 
of ONPG to the colorimetric molecule ONP. This measurement of p-gal activity was 
converted to Miller Units in order to take into account the cell number and length of time 
for color development in contrast to the indicator plate method that does not take 
bacterial cell numbers into account. The background level of interaction in the Cyal8-
Empty/ Cya2s-Empty co-expressing strain was subtracted from the Miller Units for each 
sample. 
Extracts from DHMI strains co-expressing SIcI and TARP indicated 3-fold 
higher level of p-galactosidase production compared to the strain containing Slc2 and 
TARP (Figure 14). Both the Slc2/TARP and Sccl/TARP co-expressing DHMI extracts 
contained roughly 5-fold less p-galactosidase than the Slcl/TARP coexpressing strain. 
These results confirm the findings for a TARP-SIcl interaction shown on indicator plates 
and in the co-immunoprecipitation assay. 
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Figure 14. f3-galactosidase activity of TARP:chaperone bacterial 2-hybrid 
interactions. 
The relative beta-galactosidase activity of E.cali DHMI strains co-expressing Cyal8-
TARpl-2oo and Cya25 -SIc1 , Cya25 -Slc2, Cya25 -Sccl or Cya25 -Mcsc. Activity is expressed 
as Miller Units after subtraction of the background Cya25-Empty: Cya l8-Empty 
interaction. Data is representative of multiple trials. 
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Interaction of SIc] with TARP from other Chlamydiae. 
SIc 1 is highly conserved between chlamydial species, but there is a complete lack 
of amino acid similarity between the N-termini of different chlamydial TARPS. 
Alignment of the secondary sequence of the N-terminal200 amino acids ofTARP from 
Ctrachomatis L2, Cmuridarum (MoPn), Ccaviae (GPIC), and C pneumoniae with the 
bioinformatics program ClustalW indicated conserved and semi-conserved features 
among the sequences (Figure 15). Several hydrophobic sites (in red) were spatially 
conserved between TARPs, and closer inspection reveals that these hydrophobic sites are 
flanked by conserved threonines and serines. However these features are conserved only 
through the N-terminal 100 amino acids, indicating a possible chaperone binding site 
within these T ARPs. This alignment led us to believe that SIc 1 from the L2 serovar 
could possibly interact with the other chlamydial TARPS. 
I first chose to look at the localization of putative chlamydial chaperones to full 
length Chlamydia caviae (GPIC) TARP due to its ability to form aggregates in 
mammalian cells. Full length TARP contains C-terminal actin-nucleating domains that 
are prone to aggregation and forms a characteristic string-of-pearls pattern when over-
expressed in mammalian cells. I was able to acquire the GPIC-GFP-TARP vector 
encoding a C-terminal GFP (green fluorescent protein) from the Hackstadt lab at Rocky 
Mountain Laboratories. The three putative chlamydial chaperones SIc 1, Sccl, and CT663 
were PCR-amplified from L2 genomic DNA and subcloned into the Invitrogen 
pENTRIDITOPO entry vector (Figure 16). The attLl and attL2 recombination sites on 
this vector allow for recombination into a number of Destination vectors with the 
homologous sites attR and attB. For mammalian expression with an N-terminally fused 
58 
Mcherry protein I recombined the chaperones from the entry vector into pDEST-N-
Mcherry (Figure 16). This allowed us to look for co localization of the red chaperones 
with green aggregates of GPIC TARP. 
The vectors GPIC-GFP-TARP and Mcherry-gus, Mcherry-Slc1, or Mcherry-Slc2 
were co-transfected into Cos-7 cells and the co-localization of recombinant proteins was 
visualized by confocal microscopy (Figure 17). While the host cytosolic protein, gus 
localized some with TARP aggregates, this is probably just due to bleed-through from the 
green channel into the red channel. Slc2 localized to the T ARP aggregates to the same 
extent as gus indicating a negative result for interaction. However, SIc 1 overwhelmingly 
co localizes with T ARP aggregates in this assay. Of the two putative chaperones, only 
SIc! was specifically recruited to TARP, confirming it as the specific type III chaperone 
for TARP and indicating that SIc1 can interact with the N-terminus ofTARP from 
multiple chlamydial species. 
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Figure 15. Amino acid alignment of the N-terminus of TARP from different 
pathogenic Chlamydiae. 
The N-terminal200 amino acids ofTARP from C caviae (GPIC), C pneumoniae (CPn), 
C trachomatis (L2), and C muridarum (MoPn) were aligned with clustalW. Residues in 
red indicate regions of conserved hydrophobicity, while light blue indicates conserved 
residues. 
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Figure 16. Diagram of the recombination vectors used to express chaperones in 
mammalian cells. 
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GPIC GFP~TARP + 
MCherry·gus 
GPIC GFP-TARP + 
Mcherry-Slc1 
GPIC GFP~TARP + 
Mcherry-Slc2 
GFP Mcherry Merged 
Figure 17. Localization of SIc! to full-length C. caviae TARP aggregates 
IOOX magnified images from confocal microscopy reveal colocalization of GPIC T ARP 
and SIcI in cotransfected Cos-7 cells. Cells were co-transfected with GPIC-GFP-TARP 
and Mcherry-gus (host cytosolic protein), Mcherry-Slc 1, or Mcherry-Slc2. 
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I continued to test the two other chlamydial T ARPs for their ability to bind L2 
SIc1. Interactions between Cpneumoniae and Cmuridarum TARP with SIc1 were tested 
by co-immunoprecipitation with M2 Anti-FLAG agarose fo llowed by immunoblotting. 
Addition of SIc 1 and Cpn or Mopn T ARP expression lysates allowed for their interaction 
which was confirmed by the presence of both of these T ARP species in the S 1c1-
containing elution fractions (Figure 18). 
aFLAG 
Lys FT FW E 
SIc1 
SIc1 + MO.Pn TARP 
SIc1 + C.Pn TARP 
a6XHIS 
Lys FT FW E --
Figure 18. Pulldown of the N-terminus of C. muridarum and C. pneumoniae TARPs 
with SIc1. 
Immunoblots of the lysates (Lys), flow-through (FT), final wash (FW), and elution (E) 
fractions from M2 Anti-FLAG immunoprecipitated recombinant SIc1 and the N-terminal 
200 amino acids of C. muridarum (MoPn) or C. pneumoniae (C.Pn) TARPs are probed 
with their respective antibodies. 
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CHAPTER IV 
IDENTIFICATION AND CHARACTERIZATION OF CHLAMYDIAL 
CHAPERONE: CHAPERONE INTERACTIONS 
Specific interaction between the chaperone SIc I and TARP prompted us look 
deeper into the relationship of this chaperone: effector interaction. Translocation 
chaperones typically exist as either as a homodimer or a heterodimer prior to their 
interaction with their cognate effectors. Since our negative results for interaction 
between Slc2 or Scc I and T ARP only included possibly homodimers, I felt it necessary 
to see if the formation of SIc2-Slc I or Scc I-SIc I heterodimers could contribute to T ARP 
binding. I chose to characterize all possible chlamydial chaperone dimers to reveal any 
interactions that could be important for binding with TARP and other chlamydial 
effectors. 
Discovery of chlamydial chaperone: chaperone pairs 
Therefore, I investigated the ability of SIc I to form homodimers with itself or 
heterodimers with either SIc2 or Scc I using both co-immunoprecipitation and bacterial 
two-hybrid techniques. As before, I are taking advantage of separate recombinant tags on 
the proteins to purify protein complexes and to detect the protein composition of these 
complexes by Western blot analysis. I first wanted to detect whether SIcI can interact 
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with itself or with other chaperones so I employed M2 Anti-FLAG agarose and Anti-S-
tag resin to purify chaperone dimers. 
By co-immunoprecipitating Flag-tagged SIcI (Slel-F) with S-tagged SIcI (SIcI-
S) on M2 Anti-FLAG beads, I was able co-elute them from the beads and thus 
demonstrate that Slel can multimerize with itself (Figure 19). However I could not 
detect any co-elution of SIc2-F with SIcI-S following immunoprecipitation on M2 
agarose, indicating a lack of interaction between the two proteins. Similarly, I was also 
able to detect an interaction between SIcI-S and Slcl-F by co-immunoprecipitation with 
S-Rek resin, but not between Sccl-S and SIcI-F (Figure 20). In both co-
immunoprecipitation assays detection of the SIcI: SIcI interaction was minimal. This is 
not surprising considering the fact that many known type III secretion chaperones in 
other bacteria preferentially form dimers in solution, leaving few monomers around for 
potential dimer formation in our assay. 
65 
aFLAG as-tag 
FT W1 FW E FT W1 FW E 
SIc1 ~S 
Slc1-F 
Slc1-F + Slc1 -S 
Slc2-F 
Slc2-F + Slc1-S 
Figure 19. Pulldown of FLAG-tagged SIc1 and Slc2 in the presence of S-tagged SIc1. 
Irnmunoblots of the FT (flow-through), WI (first wash), FW (final wash), and E (elution) 
fractions following M2 Anti-FLAG co-irnmunoprecipitation of FLAG-tagged chaperones 
(SIc1-F or Slc2-F) in the presence or absence of S-tagged SIc1 (SIc I-S) from co-
expressed BL21 E. coli lysates were detected with aFLAG or as-tag antibodies, 
respectively. 
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SIc1 Scc1 
FT W1 FW E FT W1 FW E 
Slc1-F 
Scc1-S 
Scc1 -S + Slc1-F 
Figure 20. Pulldown of SIc1 in the presence of Scc1. 
Immunoblots of FT, FW, and E fractions following S-Rek resin immunoprecipitation of 
Sccl-S in the presence or absence of Slcl-F were detected with antibodies against their 
respective tags . 
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Therefore I continued to investigate these interactions by E.coli 2-hybrid analysis, 
testing all possible chaperones: chaperone interactions. I was able to detect interactions 
between Cyal8-Slci :Cya2s-SlcI, CyaI8-Mcsc: Cya25-Mcsc, and CyawSlc2:Cya2s-Sccl 
by blue and fuchsia colonies on X-gal and McConkey plates, respectively (Figure 21). 
The Mcsc:Mcsc and Slc2:Sccl interactions had been previously identified in a recent 
yeast-two hybrid study [49]. I tested the expression of the CyawSccl and Cya2s-Slc2 
recombinant proteins to try to understand why the reciprocal 2-hybrid didn't indicate 
interaction, and was able to detect expression of both by coomassie staining (data not 
shown). All other chlamydial chaperone: chaperone interactions were similar to the 
negative control, and did not produce an obvious color change to blue or fuchsia on 
indicator media. 
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Figure 21. Bacterial 2-hybrid interactions between chlamydial chaperones. 
LB + X-gal + IPTG (left) or McConkey + maltose (right) agarose plates indicate 
interaction between co-expressed Cya15 or Cya18 fused chlamydia) chaperones in the 
cya deficient E coli strain DHMI. Upregulation of the lactose and maltose operons 
results from fusion-protein interaction and is indicated by blue or fuchsia bacteria. 
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Quantitative analysis of the ~-galactosidase activity of the Cyals-ehaperone I 
Cya2s-chaperone co-expressing strains indicated a very strong interaction between CyalS-
Mcsc and Cyals-Mcsc, whereas the SIcI :SIc1 and SIc2:Scci interactions were stronger 
than the background chaperone: chaperone interactions (Figure 22). Other chaperone: 
chaperone interactions were higher than background levels but still lower than the 
interactions that had been previously confirmed on indicator plates. Taken together, these 
bacterial 2-hybrid data indicate a novel SIc I-Slc1 interaction and confirms the previous 
Mcsc-Mcsc and Slc2:Scc1 interactions that were discovered in a recent yeast 2-hybrid 
study. All together the co-immunoprecipitation and bacterial 2-hybrid results indicate that 
SIc I forms homodimers, but not heterodimers. Given our previous findings that TARP 
does not interact with Sec1 or SIc2, it is likely that only Sici homodimers interact with 
TARP. 
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Figure 22. Quantitative analysis of bacterial2-hybrid chaperone: chaperone 
interactions, 
The relative beta-galactosidase activity of E.coli DHMI strains co-expressing the 
recombinant Cya 18 -chaperones and Cya25 -cha~erones. Activity is expressed as Miller 
Units after subtraction of the background Cya 5-Empty: Cya l 8-Empty interaction. Data is 
representative of multiple trials. 
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Determination of the molecular composition of ScI homo-complexes 
I expect the apparent SIcI :SIcI interactions shown by co-immunoprecipitation 
and bacterial2-hybrid analysis was a result of the formation ofhomodimers, however the 
rare case of trimer and tetramer forms of type III chaperones have also been observed to 
interact with type III effectors in other bacteria. I chose to detect all native SIc1 complex 
forms by stabilizing their interaction with a crosslinker and separating the complexes on 
an SDS-PAGE gel. Since I wanted to crosslink M2-Anti-FLAG agarose purified SIc1 in 
PBS, I chose to use a hydrolysable crosslinker that could be reduced in the presence of p-
mercaptoethanol (BME), but not in its absence. In addition I wanted to use a crosslinker 
that would react with the primary amines (mostly N-termini) of purified proteins. The 
compound DTSSP binds cysteines and primary amines at both ends and has been 
modified from its original non-hydrolyzable form, DSP, to be able to dissolve and react 
in solution. (Figure 23) Crosslinking of purified FLAG-SIc 1 with the hydrolysable 
DTSSP reagent revealed the ability of this protein to form a dimer in the absence of the 
crosslinker; this dimeric complex was able to withstand denaturation in the SDS-PAGE 
gel (Figure 23). In fact, purified SlcI that was reduced (BME) and heated to 90°C, but 
not crosslinked still showed faint dimerization at the expected ~40 kDa size. The 
addition a small concentration of crosslinker (0.25 mM) revealed a higher molecular 
weight SIcI complex with a size (~60 kDa) consistent with trim eric species. Since non-
crosslinked, non-reduced purified SIc 1 readily migrated to a dimer-sized position on a 
non-reducing SDS-PAGE gel it is clear that SIc1 forms stable dimers. 
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Figure 23. Stabilizing SIc1 complexes by the crosslinker DTSSP. 
Multimerization of Slcl. (Top) Chemical structure of the crosslinker 3,3' -Dithiobis 
(sulfosuccinimidylpropionate (DTSSP). (Bottom) An immunoblot of ~-mercaptoethanol 
(~ME), mock-treated (-), or 0.25 mM DTSSP crosslinked (+) purified SIcl was probed 
with aFLAG antibody following separation in 12% SDS-PAGE gel under non-reducing 
conditions. 
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While I was able to detect dimerization of SIc 1 by crosslinking, the presence of a 
trimeric species required independent confirmation using gel filtration chromatography, 
which is a more gentle analytical technique that did not requiere crosslinking. Upon 
purification of SIc I-FLAG with M2 Anti-FLAG agarose, I loaded 50 III of 100 ng/ml 
purified SIcl into a Superdex 200 10/300 GL column in PBS. The column washes the 
protein through sepharose gel with additional PBS. Larger species get stuck in the gel 
sooner, and thus get eluted from the column first. Prior to elution of 500 III fractions 
along the length of the gel, the relative abundance of the protein is detected at a 
wavelength of 280 nm. 
The relative abundance of protein in each of the eluted fractions is shown on the 
y-axis, while the relative size of each species (peak) is indicated by the elution fractions 
on the x-axis. Each elution fraction was monitored for SIcI content by Western blot. 
Higher molecular weight complexes are eluted earlier. Only one prominent peak was 
detected for the SIcI complex and when compared to known molecular weight standards 
in PBS, it was determined to be ~40 kDa in size (Figure 24). SIc1 was detected in the 
TCA-precipitated elution fractions under the dimeric peak by immunoblotting. 
Crosslinking and gel filtration of purified SIc 1 indicates that it preferentially forms 
homodimers, indicating that this is the form it likely takes when interacting with TARP. 
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Figure 24. Detection of native SIc1 species by gel filtration chromatography 
The relative abundance of native M2-purified SIc1 complexes were detected and eluted in 
500 ul fractions by gel filtration chromatography. An immunoblot of trichloracetic acid 
(TCA)-precipitated fractions was detected with aFLAG antibody. 
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CHAPTER V 
FUNCTIONAL DETERMINATION OF SLCI IN THE TRANSLOCATION OF 
TARP BY HETEROLOGOUS TYPE III SECRETION SYSTEMS 
TARP: SIc1 complexes indicate the expected 2:1 stoichiometry o/type III chaperone: 
effector interactions 
I was able to detect a complex formed between SIc I and T ARP by detection of a 
shift in complex size between purified recombinant T ARP and T ARP co-expressed in the 
presence of SlcIon a silver-stained native gel and on its corresponding 6XHIS-probed 
immunoblot. Since native gels separate proteins based on their shape and size, it is 
difficult to extrapolate an approximate molecular weight of the complex (Figure 25). 
To gain some insight into the composition of the complex formed by TARP and 
SIc I, a similar chromatography approach was used to analyze purified HIS6-TARP 1-200 
and the HIS6-TARpl-200 /SIcI-FLAG complex. The chromatography conditions produced 
readily identifiable peaks for HIS6-TARp
l-200 from SIc1-FLAG quite easily (Figure 26). 
To determine the approximate size of the protein complex formed by T ARP and 
SIcI, the Ni-Nta agarose eluates from lysates containing co-expressed HIS6-TARpl-200 
and SkI-FLAG were subjected to gel filtration chromatography. Ni-Nta purified protein 
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from the lysate containing HIS6-TARp
l
-
200 was used as a reference control. The Sic 1 and 
T ARP content of the co-expressed elution fractions was detected with antibodies against 
their respective tags by Western blot. Since the co-expressed complex was purified with 
Ni-Nta agarose, I expect the sample to contain both monomeric TARP and TARP in a 
complex with Sic 1. Here I see that TARP-containing elution fractions correspond to a 
peak between 13.9 kDa and 29 kDa and a peak >75 kDa, while Slcl is present only in the 
elution fractions corresponding to the >75 kDa peak. These sizes are in agreement with 
monomeric T ARP and a l:2 complex of TARP to SIc 1. Taken together with our SIc 1 
dimerization data, the results indicate that a dimer of the Slcl chaperone forms a complex 
with one molecule ofHIS6-TARp l -200 when co-expressed. In order to detect the Slcl-
TARP complex by chromatography, co-expression of Sic land TARP appeared to be 
necessary because the addition of pre-purified components failed to produce a similar 
>75 kDa-peak (Figure 27). 
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Figure 25. Native gel shift ofTARP: SIc! complex 
Native purified protein complexes are shown on both silver stain and Western blot. All 
protein species from the purified fractions are displayed on the silver-stained Native 
PAGE gel on the left. TARP-containing complexes are detected in the identical purified 
fractions with u6XHIS antibody on the immunoblot on the right. Arrows indicate the 
complex formed under co-expressing conditions. 
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Figure 26. Detection ofTARP: SIc1 native complex (coexpressed). 
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Separation and detection of co-expressed SIc 1: T ARP complexes. The relative 
abundances of native NiNta-purified TARP I -2oO complexes alone or co-expressed with 
SIc1 were detected and eluted in 500 ul fractions (top) by gel filtration chromatography. 
Immunoblots of the TeA-precipitated elution fractions were detected with a6XHIS and 
aFLAG antibodies (bottom). 
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Figure 27. Detection ofTARP: SIc1 native complex (Combined). 
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The separation and detection of M2-purified Sic 1 (Red), Sic 1 + TARP (Blue), or Ni-Nta-
purified T ARP (Green) was achieved by gel filtration chromatography. The peaks on the 
chromatogram correspond to the molecular weight standards (top). The relative 
abundances at A280 are indicated by the y-axis and the corresponding immunoblots of 
the 500).!1 fractions on the x-axis were TeA-precipitated and detected with a6XHIS and 
aFLAG antibodies. 
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Translocation of TARP by heterologous type III secretion systems 
While the biochemical data suggests that SIc 1 interacts with TARP in a fashion 
typical of type III chaperone: effector complexes, I desired to know what role SIc1 plays 
in TARP translocation by the chlamydial type III secretion apparatus. Unfortunately, 
Chlamydia's lack of a genetically tractable system prevented us from directly testing 
SIc 1 's role in TARP's translocation from the chlamydial EB into mammalian epithelial 
cells. Fortunately, I was able to express our recombinant chlamydial proteins in the 
pathogenic bacteria Yersinia enterocolitica, Enteropathogenic E. coli (EPEC), and 
Salmonella typhimurium and detect T ARP' s translocation through their heterologous type 
III secretion apparatuses into Hela cells. 
To accomplish this, I took advantage of an existing translocation assay that 
involved expressing possible effectors in the pCX340 vector that C-terrninally fuses them 
to enzymatically active p-Iactamase, and the chaperones were cloned into an arabinose-
inducible expression vector pBAD I8-Cm (Figure 28). The chaperones were amplified 
from C. trachomatis L2 genomic DNA by PCR (Figure 29) and cloned into the KpnI and 
XbaI sites on the vector. A KpnI site was added downstream of the TARp l -200 open 
reading frame in the pET200-TARp l-2oO vector by SLIM PCR (Figure 30), while TARP 
was cloned into the NdeI and KpnI sites ofpCX340 (Figure 31). 
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Figure 28. Diagrams of the bacterial expression vectors pBAD18-Cm and pCX340. 
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Figure 29. Cloning chlamydial chaperones into the pBAD18-Cm vector 
(Top) Insert PCRs ofCT043 and Mcsc open-reading frames with flanking XbaI and Seal 
sites. (Bottom) Colony PCRs from chloramphenicol-selected pBAD I8-chaperone 
transformants. 
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Figure 30. Adding a KpnI site to the pET200-TARP200 construct by SLIM peR. 
(Top) Si te-directed Lipase-Independent Mutagenesis (SLIM) based PCR was performed 
to add a KpnI site downstream of the T ARP200 open reading frame in the pET200-
TARP200aa vector and the PCR product is displayed here on a 0.7% Agarose gel. 
(Bottom) pET200-TARP200aa-KpnI plasmid DNA prepared from kanamycin-selected 
Bl21 star E.coli transformants were checked for the presence of a KpnI site by restriction 
digest as displayed here on a 0.7% Agarose gel. 
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Figure 31. Cloning TARP into the pCX340 vector. 
(Top) The TARP200aa open reading frame was digested with Kpnl and NdeI from the 
pET200-TARP200 vector and pCX340 was double digested as well prior to ligation as 
indicated here on the 1 % Agarose gel. (Bottom) Colony PCR was performed on 
tetracycline-selected transformants and separated on a 1.2% Agarose gel. 
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Upon contact with mammalian cells, the bacteria will translocation their type III 
effectors into the host cell. Treatment of the HeLa cell mono layers with CCF21 AM, a 
coumarin molecule bound to hexane by a 0-lactam ring, following infection allows for an 
especially innovative fluorescence assay that takes advantage of the fact that the intact 
substrate fluoresces at 520 nm and the cleavage product, coumarin, fluoresces at 450 nm 
(after excitation at 410 nm). The presence ofTEMI-fused bacterial effectors in the host 
cell is reflected in the cleavage of the b-Iactam ring to release the coumarin molecule, 
which I can measure its fluorescence at 450 nm. Thus I can detect fluorescence 
resonance energy transfer, (FRET) of the intact molecule in the green spectrum at 520 
nm, while I can detect cleavage of the substrate as a loss of FRET in the blue spectrum at 
450 nm. A diagram of the basis of this assay is shown in Figure 32. 
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Figure 32. Diagram of the CCF2/AM fluorescence-based translocation assay 
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In the bacterial cell, ~-lactamase fused TARP is expressed from the pCX340-T ARP 
vector. Two hours post-infection of He La cell monolayers, cultures are treated with 
CCF2/AM, a molecule that undergoes FRET (Fluorescence Resonance Energy Transfer) 
when excited at 410 run and emits fluorescence in the green spectrum at 450 run. 
Translocation of ~-lactamase fused TARP by the bacterial Type III Secretion System 
(T3 SS) into the eukaryotic cell and subsequent cleavage of the ~-lactam ring portion of 
CCF2/AM results in a loss of FRET and an alternate emission of fluorescence in the blue 
spectrum at 450 nm. 
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The Yersinia ysc family type III secretion system is encoded on its virulence 
plasmid[63]. The type III secretion system from Yersinia pseudotuberculosis has been 
previously used to express and secrete chlamydial translocators and effectors, including 
TARP, into low-calcium media[38, 41,150]. I was also able to detect TARP secretion 
into media by wild-type Yersinia enterocolitica similar to levels of secretion of the 
Yersinia effector, Y opH (Figure 33). 
However, Yersinia strains have not been tested for their ability to translocate 
chlamydial proteins into eukaryotic cells. I chose to utilize the type III secretion system 
of Yersinia enterocolitica to determine the role of Slcl in the secretion and translocation 
of T ARP. Based on previous findings, I expect that some TARP will be secreted and 
possibly translocated in the absence of its cognate chaperone [ 42]. However, our 
interaction studies indicate that the chaperone Slc 1 binds T ARP in a fashion typical of 
export chaperones convincing us that SIc1 will enhance TARP's interaction with the type 
III secretion apparatus and thus increase the amount T ARP secreted or translocated by 
the Yersinia enterocolitica type III secretion system. 
Wild type and type III ATPase (Y scN) knockout strains of Y. enterocolitica expressing 
TARP ±-SIc1 were allowed to infect HeLa cell monolayer for 2 hours prior to CCF21 AM 
treatment. A loss of FRET (p-Iactamase-mediated cleavage) to FRET (no cleavage) ratio 
was used to detect translocation. Translocation of the positive control, Y opH was 
detected at a fluorescence ratio of ~0.8, and the negative control empty vector indicated 
at ratio ofless than 0.1 (Figure 34). I was able to detect SIc1-mediated translocation of 
TARP as indicated by the ratio of 0.67 by co-expressing bacteria and 0.43 from TARP-
only expressing bacteria. Because the Y scN knockout strains were unable to translocate 
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any effectors, I can be absolutely positive they are being translocated through the 
Yenterocolilica type III secretion needle. 
-Ca -Ca +Ca -Ca -Ca -Ca 
WT WT WT dYscN WT dYscN 
pcx-Empty pcx-YopH pcx-YopH pcx-YopH pcx-TARP pcx-TARP 
S P S P S P S P S P S P 
-
Figure 33. Secretion of HIS6-T ARPl -200 by the Yersinia enterocolitica type III 
secretion system. Immunoblots of TCA-precipitated Yersinia enterocolitica culture 
supernatants (S) and whole cell pellets (P) under type III secretion inducing conditions (-
Ca) or repressing conditions (+Ca) were probed with ~-lactamase mAb. Secretion was 
tested by wild-type (WT) or type III secretion knockout (dYscN) Yersinia enterocolitica 
strains. 
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Translocation of TARP by the Yersinia enteroco/itica T3SS 
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Figure 34. Translocation of T ARP by Yersinia enterocolitica. 
The fluorescence ratio of cleaved CCF2/AM substrate (450 nm) to uncleaved substrate 
(520 nm) indicates the relative translocation of B-Iactamase fused effectors by the ysc 
type III secretion system of Y enterocolitica. Wild-type (WT) and the Type III ATPase 
yscN knock-out (T3KO) strains bearing the B-Iactamase fusion vector pcx340 with or 
without pBAD-Slcl were allowed to infect HeLa cells prior to treatment with CCF2/AM 
substrate and fluorescence detection. 
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I next used the Enteropathogenic Escherichia coli (EPEC) to test the translocation 
of T ARP. To date there has been no evidence of secretion of chlamydial proteins by the 
EPEC type III secretion ofTARP. However, EPEC is known to translocate the type III 
effector Tir that has very similar function in vivo as TARP. They both induce massive 
cytoskeleton rearrangement to ensure close attachment and survival of the bacteria. 
Furthermore alignment of type III secretion chaperones has revealed that Tir's cognate 
chaperone CesT has very similar secondary structure as SIc 1. Therefore I thought it 
likely that the EPEC type III secretion could translocate TARP in the presence of its 
cognate chaperone SIc1. 
EPEC attaches to epithelial cells and begins to translocate its effectors as soon as 
30 minutes post-infection. I was able to detect translocation of the EPEC effector EspH 
as a fluorescence ratio of 1.5 after 1 hour of infection. Using the same infection 
conditions I was unable to detect any chaperone-dependent or -independent translocation 
of T ARP. (Figure 35), and lengthening the duration of infection did not change this 
negative result (data not shown). 
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Fig 35. Translocation of TARP by Enteropathogenic E. coli 
The fluorescence ratio of cleaved CCF21 AM substrate (450 run) to uncleaved substrate 
(520 run) indicates the relative translocation of ~-lactamase fused effectors by the type III 
secretion system of Enteropathogenic E. coli (EPEC). Wild-type (WT) and the Type III 
ATPase escN knock-out (T3KO) EPEC strains bearing the ~-lactamase fusion vector 
pcx340 with or without pBAD-Slcl were allowed to infect HeLa cells prior to treatment 
with CCF21 AM substrate and fluorescence detection. 
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Salmonella typhimurium contains two functional type III secretion systems that 
are temporally regulated and are responsible for translocating distinct sets of effectors 
into epithelial cells. The SPI -1 (Salmonella pathogenicity island-I) type III secretion 
system translocated effectors upon contact with host cells to induce uptake of Salmonella 
into endocytic vesicles. After complete engulfment of the bacterium, it switches to 
secretion of effectors involved in maintaining its Salmonella-containing vesicle (SCV) 
and in redirecting host cell vesicle trafficking to ensure its intracellular survival[63]. 
Because the SPI -1 T3 SS is responsible for secreting proteins involved in invasion of 
eukaryotic cells, it is an attractive choice for testing TARPs translocation. However, the 
SPI-2 system resembles that of Chlamydia because of its ability to secrete from an 
intracellular vesicle indicating that it also is worth trying as a heterologous secretion 
system. 
As indicated by the fluorescence ratios of infected mono layers, the Salmonella 
SPI-l secretion system was unable to translocate TARP under any conditions (Figure 
36), but the SPI-2 system seemed to minimally translocate TARP in a chaperone-
independent manner, but achieved efficient translocation of TARP in the presence of its 
cognate chaperone SIcl (Fig 34). However the high ratios for the ~-lactamase only 
(pcx340-Empty) translocation casts some doubt on the reliability of this assay under SPI-
2 conditions. Furthermore, this assay has remained untested for translocation during 
intracellular growth (8-12 hours post-infection); instead its use has been for detection of 
translocation of substrates immediately after attachment (1-3 hours post-infection). 
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Figure 36. Translocation ofTARP by Salmonella typhimurium SPI-l and SPI-2 
The fluorescence ratio of cleaved CCF2/AM substrate (450 run) to uncleaved substrate 
(520 run) indicates the relative translocation of ~-lactamase fused effectors by the SPI-l 
and SPI-2 type III secretion systems of Salmonella typhimurium. Wild-type (WT) 
Salmonella strains bearing the ~ -lactamase fusion vector pcx340 with or without SIcI 
were allowed to infect BeLa cells prior to treatment with CCF21 AM substrate and 
fluorescence detection. SPI- l mediated translocation was detected 2 hours post-infection, 
while SPI-2 mediated translocation was detected 10 hrs post-infection . 
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The differences in T ARP translocation by different heterologous type III secretion 
systems is likely to due to the inability of the cytoplasmic components from other type III 
secretion systems to recognize the TARP-Slcl complex. To gain insight into this 
possibility, I analyzed the relatedness of the chlamydial type III A TPases CdsN and FliI 
with the type III A TPases from Salmonella, Yersinia, and EPEC. The amino acid 
sequences of these paralogs were aligned with ClustalW and the resulting alignments 
were organized into unrooted dendograms (Figure 37). The CdsN tree indicates that 
Yersinia type III ATPase YscN and the SPI-2 ATPase SsaN are similar to the non-
flagellar chlamydial ATPase, while the A TPases from the SPI -1 and EPEC are less 
closely related, supporting our findings that Yersinia type III system and the Salmonella 
SPI-2 system could both recognize the TARP: chaperone complex and subsequently 
translocate TARP into HeLa cells. Furthermore, phylogenetic analysis indicates that the 
chlamydial flagellar type III ATPase FliI is more similar to the EPEC and SPI -1 non-
flagellar ATPases than to relevant ATPases in Yenterocolitica and the Salmonella SPI-2 
systems. 
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Figure 37. Phylogenetic analysis of multiple type III components from bacterial 
pathogens. 
Flil 
Unrooted phylograms were created from ClustalW-generated multiple sequence 
alignments of the C pneumoniae (cpn) and Ctrachomatis (ctr) ATPases CdsN (top) and 
FliI (bottom) with the relevant ATPases from S. typhimurium (stm), and 
Enterropathogenic E.coli (ecg). Orthologs were identified for comparison by the Kyoto 
Encyclopedia of Genes and Genomes (KEGG). 
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TABLE 5. STRAINS AND PLASMIDS USED IN THIS STUDY 
Strains 
Top 10 (DHI0B) 
BL21 (OE3A) 
OHMI 
E2348/69 
ICCI92 
12023s 
HHI09 
MRS40(p YV 40) 
MRS40(pMSL41 ) 
Plasmids 
pEGFP-TARP 
N-MCherry-
pOEST 
pMch-Slcl 
pMch-Slc2 
pMch-Sccl 
pETI0l 
pET200 
pENTR-O/SD-
TOPO 
pET56-0EST 
pSlcl-FLAG 
pS1c2-FLAG 
pTARP200 
p56-Sccl 
p56-S1cl 
pUT18C 
pKT25 
pI8C-TARP 
pl8C-Tir 
p18C-CT043 
p18C-CT088 
p18C-CT260 
p18C-CT663 
p25-CT043 
p25-CT088 
p25-CT260 
p25-CT663 
p25-CesT 
Description 
E.coli high-level propagation 
E.coli high-level expression 
Adenylate cyclase deficient E.coli 
Wild type EPEC 0127:H6 
EPEC E2348/69~escN 
Wild type Salmonella enterica typhimurium 
ssaV::aphT in 12023 (Kmr) 
Yersinia enterocolitica, ampicillin-resistant derivative 
Y scN ATPase knockout of MRS40 
full length C.caviae TARP in pEGFP-CI vector 
pCONA 6.2 derived vector with N-terminal Mcherry 
N-Mcherry-pOEST expressing SIcI 
N-mcherry-pOEST expressing S1c2 
N-mcherry-pDEST expressing Sccl 
directional TOPO expression vector 
directional TOPO expression vector 
directional TOPO entry vector for LR recombination 
bacterial expression destination vector (LR) 
pETI0l expressing SIcI-FLAG 
pETI0l expressing S1c2-FLAG 
pET200 expressing N-terrn 200aa ofL2 TARP 
pDEST-56 expressing Sccl-FLAG 
pOEST-56 expressing S1cl 
E.coli 2-hybrid vector - cya fragment 18 fusion 
E.coli 2-hybrid vector - cya fragment 25 fusion 
E2H -cya-18 fragment fused to Nterrn 200aa T ARP 
E2H -cya-18 fragment fused to Nterm 200aa Tir 
E2H -cya-18 fragment fused to CT043 
E2H -cya-18 fragment fused to CT088 
E2H -cya-18 fragment fused to CT260 
E2H -cya-18 fragment fused to CT663 
E2H -cya-25 fragment fused to CT043 
E2H -cya-25 fragment fused to CT088 
E2H -cya-25 fragment fused to CT260 
E2H -cya-25 fragment fused to CT663 
E2H -cya-25 fragment fused to CesT 
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Reference 
Life Technologies 
Life Technologies 
Karimova,G (1995) 
Levine et al (1978) 
Garmendia et al 
(2004) 
NCTC 
Deiwick et al.(1999) 
Sory,M.P. (1994) 
Sory,M.P. (1995) 
Lane et aI, (2008) 
Scott Grieshaber 
This study 
This study 
This study 
Invitrogen 
Invitrogen 
Invitrogen 
Novagen 
This study 
This study 
This study 
This study 
This study 
Karimova,G (1998) 
Karimova,G (1998) 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
pCX340 
pBAD-TOPO 
pBADl8 
pCX340-
TARP200 
pCX340-PipB2 
pBAD-CT043 
pBAD-CT088 
pBAD-CT260 
pBAD-CT663 
TEMl fusion, IPTG inducible 
Arabinose-inducible promoter 
Arabinose-inducible promoter 
N-term 200aa ofTARP fused to TEMl 
N-term 200aa ofPipB2 fused to TEMl 
pBAD-TOPO with CT043-FLAG insert 
pBADl8 with CT088-FLAG insert 
pBAD-TOPO with CT260-FLAG insert 
pBAD18 with CT663-FLAG insert 
Charpentier (2004) 
Invitrogen 
Guzman (1995) 
This study 
This study 
This study 
This study 
This study 
This study 
Primers 
AJBIF 
AJBIR 
AJB2F 
AJB2R 
AJB3F 
AJB3R 
AJB4F 
AJB4R 
AJB5R 
AJB6FT 
AJB6FS 
AJB6RT 
AJB6RS 
AJB7FT 
AJB7FS 
AJB7RT 
AJB7RS 
AJB8F 
AJB8R 
AJBIOF 
AJBIOR 
AJBl3R 
AJBl4F 
AJBI4R 
AJBl5F 
AJBl5R 
AJBl6F 
AJBI6R 
AJBI7F 
AJBI7R 
AJBI8F 
AJBI8R 
AJBl9F 
TABLE 5. PRIMERS USED IN THIS STUDY 
Sequence 5' => 3' 
CACCATGTCCAGGCAGAATGCTGA 
TCACTTGTCATCGTCGTCCTTGTAGTAGCACGGATTCCTGCGGTA 
CACCATGTTGGAAAAATTGATAAAGAATTTTGTGGCG 
TTACTCCTGCTCCGTTTTACTTAGTCTAAATC 
CACCATGCAAAATCAATTTGAACAACTC 
ATCGATTTACTTGTCGTCATCGTCCTTGTAGTCCAGGTGATACAT 
CACCATGACGAATTCTATATCAGGTGATC 
TTATCCTACGGTATCAATCAGTGAGCT 
TTATGCACGGATTCCTGTGGAGG 
CCTTCACCAAGGGTACCTCAACGATCCGGCTGCTAACAAAGCC 
CCGGCTGCTAACAAAGCC 
TCGTTGAGGTACCCTTGGAGGAGCCTCTTAGAGA 
CTTGGAGGAGCCTCTTAGAGA 
CGATTAAATAAGGAGGAATAACATATGACGAATTCTATATCAGGTGATC 
ACGAATTCTATATCAGGTGATCAACCTA 
CATATGTTATTCCTCCTTATTTAATCGCGATACATTAATATATACCTCT 
CGATACATTAATATATACCTCTTTAATTTTTAATAATAAAG 
ACCATGGCCTCCAGGCAGAATGCT 
TTATTAGTCCTTATCGTCATCGTCCTTGTAATCTGCACGGATTCTGCT 
ACCATGGCCACAACGTGGACTTTGAATCAC 
TTATTAGTCCTTATCGTCATCGTCCTTGTAATCAGGCTCTAGCTGATCGGAT 
GAACTAACGTATGGAGAAAGGTACCCAAGCTTCCAGCAACGGCTT 
CGTAGGACGCATATGAACTTATCATTAAGCGAT 
TGAATCTCAGGTACCGCGGCTGCTGAGTTC 
TAGCATCGGGTACCGATGACGAATTCTATATCAG 
CGTAGCTATCGATGAGCCACTTGTGCTAGA 
GTTACGATCTAGAGATGCCTATTGGTAACCTTGGTAATA 
CTAGTGCAGGTACCTTACGTATCAACGTCCTT 
TTACGTATTCTAGAGATGTCCAGGCAGAATGCT 
GCATTAGTGGTACCCTTATGCACGGATTCCTGC 
TGTACCGTATTCTAGAGATGCAAAATCAATTTGAAC 
TGCTATCGGTACCTTACAGGTGATACATACCT 
TTACGTATTCTAGAGATGACAACGTGGACTTTG 
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AJBI9R 
AJB20F 
AJB20R 
AJB21F 
AJB21R 
AJB22F 
AJB22R 
AJB23F 
AJB23R 
AJB24F 
AJB24R 
AJB25F 
AJB25R 
GCATTAGTGGTACCCCTAAGGCTCTAGCTGATC 
GGACGGACTCTAGAGATGTTGGAAAAATTGATA 
GCATTAGTGGTACCCTTACTCCTGCTGCGTTTT 
TAACAGTAGGTACCTTATCTTCCGGCGTA 
TTACGTATTCTAGAGATGTCATCAAGATCTGAAC 
CATTATTCTAGAGATGTCCAGGCAGAATGCTGAG 
TTGCTAGTACCCGTTATGCACGGATTCCTGCTGG 
CATTATTCTAGAGATGCAAAATCAATTTGAACAA 
TTGCTAGTACCCGTTACAGGTGATACATACCTAG 
CATTATTCTAGAGATGACAACGTGGACTTTGAAT 
TTGCTAGTACCCGTTAAGGCTCTAGCTGATCGGA 
CATTATTCTAGAGATGTTGGAAAAATTGATAAAG 
TTGCTAGTACCCGTTACTCCTGCTCCGTTTTCTT 
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DISCUSSION 
Many intracellular bacterial pathogens use specialized secretion systems to 
translocate effectors into eukaryotic cells and in turn these effectors recruit, modify, or 
hijack cellular components to the benefit of the bacterium. Effectors of bacterial type III 
secretion systems have been reported to be involved in remodeling the eukaryotic 
cytoskeleton, altering the immune response, hijacking trafficking vesicles, disrupting 
cell-to-cell junctions, and causing cytotoxicity[ 63]. 
Survival and pathogenesis of Chlamydia spp. is entirely dependent on its ability to 
invade mammalian epithelial cells and develop a unique niche that is conducive to 
intracellular growth and replication. Translocation of effectors by a type III apparatus is 
a major strategy for Chlamydia entry, inclusion formation, and survival in eukaryotic 
cells[46, 84, 85]. Recruitment of host kinases and actin, in addition to activation ofRac 
and actin-poylmerization aid in endocytosis, and are functions attributed to the type III 
invasion associated effector TARP[42, 66, 67, 69, 132]. Chlamydia trachomatis 
urogenital, lymphogranuloma, and ocular strains synthesize T ARP homologs that contain 
three functional domains: tyrosine-rich repeats for recruitment of host kinases and 
subsequent Rac activation, a proline-rich aggregating domain, and actin-nucleating WH2-
like domains. 
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Detected and tyrosine-phosphorylated in host cells within minutes after cell 
contact, T ARP translocation is essential for the efficient uptake of C. trachomatis EBs. 
T ARP homologs in C.pneumoniae, C.caviae, and C.psittaci do not contain tyrosine-rich 
repeat domains, but they are still able to invade host cells. In addition the WH2-like 
domains are sufficient to nucleate actin in host cells, which are also important for 
infection[70, 71]. This redundancy between TARP domains indicates another possible 
function for C. trachomatis T ARP tyrosine-phosphorylation during chlamydial infection. 
It has been suggested that the tyrosine phosphorylation may help ensure specific uptake 
pathways that prevent phagolysosomal fusion. This theory has been supported by the 
detection ofTARP localized to the inclusion throughout the developmental cycle[42]. 
Given TARP's pivotal roles in entry and intracellular survival, I considered 
possible type III secretion chaperones that would increase the efficiency of T ARP 
translocation into host cells. I determined that the chlamydial chaperone SIcI specifically 
interacts with T ARP and mediates its translocation by the heterologous type III secretion 
system of Yersinia enterocolitica. Identification of putative type III related genes in 
bioinformatics studies identified three putative chlamydial effector chaperones: SIcl, 
Slc2, and Scc 1. Since Class I effector chaperones share the specific secondary structure 
a-0-0-0-a-0-0, putative chlamydial chaperones were readily identified by in silico 
approaches. Detection of these three proteins in elementary bodies indicated that anyone 
of them could be involved in maintaining T ARP in a secretion-competent state for 
immediate translocation into host cells. 
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In other gram-negative bacteria, previously identified type III Class I effector 
chaperones demonstrated binding of their effectors adjacent to their N-terminal secretion 
signal, usually within the N-terminaI30-130 amino acid range. 
Identification of the TARP's cognate secretion chaperone Slcl 
I used a direct co-immunoprecipitation approach for identifying a chlamydial 
chaperone that could interact with the N -terminal 200 amino acids of C. trachomatis L2 
TARP. I was specifically able to co-immunoprecipitate SIcI with TARP in two 
independent co-IP approaches. Separate expression of SIc 1 and T ARP in E. coli prior to 
incubation of their lysates with M2 Anti-FLAG agarose yielded an interaction between 
SIc 1 and T ARP, but co-expression of these proteins prior to co-immunoprecipitation 
greatly increased their ability to interact. This indicates to us that SIc1 may mediate 
folding of TARP or prevent its pre-mature interaction with other E. coli components when 
expressed in the same bacterium. However, neither co-immunoprecipitation technique 
was able to demonstrate an interaction between TARP and the other putative chlamydial 
chaperones SIc2 or Scc 1. 
One other explanation for the increased interaction between SIc 1 and T ARP 
during co-expresssion would be that SIcI prevents TARPs degradation or solubility. The 
cognate chaperone SycE in Yersinia helps to solubilize its cognate aggregrate-proned 
effector YopE[151], and similarly the EPEC chaperone CesT prevents the degradation of 
the effector Tir[ 152]. Despite the described ability of many known type III chaperones to 
solubilize and stabilize their effectors, I was not able to detect any changes in solubility 
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or stability of T ARP when expressed in the presence or absence of its chaperone (data not 
shown). 
One caveat of detecting chaperone: TARP interactions in Ecoli lysates, is that an 
Ecoli protein may be mediating the interaction detected between SIc! and TARP. It is 
difficult to refute this claim, because attempts to find an interaction between pre-purified 
T ARP and SIc! were unsuccessful. Because this possible E coli factor did not mediate an 
interaction between TARP and Scc! or SIc2, which are predicted to have extremely 
similar secondary and tertiary structures as SIC!, I propose that it is highly unlikely for an 
Ecoli factor to be so specific for SIcI and TARP. 
Our co-immunoprecipitation findings were confirmed by the specific interaction 
detected between SIcI and TARP in an adenyl ate-cyclase (cya) based bacterial2-hybrid 
system[I48]. Because the readout for interaction of cya-fused target and bait proteins in 
this system was the cAMP-mediated up-regulation of the lactose and maltose operons, I 
was able to detect interactions in a variety of assays. Both X-gal and McConkey plates 
indicated a range of protein-protein interactions from low-affinity (chaperone-effector) to 
high affinity (leucine-zipper proteins). While the indicator plates allowed for obvious 
qualitative results of chaperone-effector interactions, they were not able to differentiate 
between slow and fast growing strains. If allowed to grow long enough, even the 
negative control strains would begin to change color on these indicator plates, therefore I 
had concerns that any slow-growing strains would not indicate obvious interactions. 
To alleviate this problem as well as to quantitatively compare protein-protein 
interactions, I employed the ~-galactosidase assay which not only takes into account the 
amount and time of ONPG conversion, but also the total number of bacteria in each 
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sample. Compared to co-expression with other chaperones tested in this assay, DHMI 
E.coli co-expressing SIcI and TARP converted 2-3 times as much ONPG to the 
colorimetric substrate ONP, confirming the bacterial2-hybrid results on indicator plates. 
Characterizing all possible chlamydial chaperone-chaperone interactions 
The tendency of type III chaperones to dimerize prior to interacting with their 
effectors, led us to detect whether SIc 1 tends to form homodimers or heterodimers. From 
co-immunoprecipitation assays I was able detect SIcI interactions with itself, but not with 
the other putative chaperones Slc2 or Scc1. Since I singly expressed the chaperones prior 
to adding the lysates to the M2 Anti-FLAG agarose or S-rek resin, it is likely that SIcI 
dimers were formed early, leaving very little monomeric SIcI to interact with other 
chaperones. Instead of testing co-expression in the co-IP assays, I thought it best to test 
co-expressed chaperone-chaperone interactions in the bacterial 2-hybrid system. In this 
system I was able to confirm previous chlamydial chaperone-chaperone interactions as 
well as confirm our SIc I-SIc 1 interaction. Obvious interactions on indicator plates 
included SIcI-SIcI, Mcsc-Mcsc, and Slc2-Sccl. However, I was not able to detect the 
reverse Cyals-Scc1/Cya2s-Slc2 interaction indicating that the dimer formed may only 
allow interaction of the 18 and 25 fragments when the dimer is formed in the Cya18-SIc21 
Cya2S_Scc 1 orientation and not the other way around. Furthermore, I was able detect 
expression of both I8-SccI and 25-SIc2; consequently the lack of bidirectional 
interaction was not due to the constructs being problematic. 
Quantitative analysis of chaperone-chaperone interactions in the bacterial 2-
hybrid strains indicated the same positive interactions as on indicator plates, but there 
104 
also seemed to be a low level of interaction between most of the chaperones. The Slc I-
Sle 1 interaction was only 2-fold higher and the Sle2-Scc 1 interaction was only slightly 
higher than most of the chaperone-chaperone strains. I speculate that Chlamydia 
maintains a low level of interaction between type III class I chaperones to enable the 
bacterium to quickly acquire new type III effectors. This is supported by the fact that 
Candidata Protochlamydia ameobophilia maintains SycE-like Class I chaperones in the 
same gene order as in pathogenic Chalmydia, however the chaperones themselves have 
completely diverged in amino acid sequence[22, 29]. In addition, recent studies have 
identified species-specific effectors among chlamydial pathogens[84], indicating a 
mechanism for the quick selection of new type III effectors for adaptation to new host 
cell types must exist. It has been noted in other bacteria that there is little conservation in 
sequence or structure of type III effectors, despite the requirement that all effectors must 
be adequately unfolded to ensure secretion through the ~4 nM diameter needle[29, 59, 
153]. Thus type III chaperones may be necessary to partially unfold disordered regions 
in effectors so that they may effectively interact with the type III ATPase[59, 153]. 
Akeda et al. maintain that the ATPase actually does the majority of unfolding 
effectors in addition to providing active (ATP-dependent) separation of effectors from 
cognate chaperones[59]. Recent crystallizations of chaperone: effector complexes 
support this theory that chaperones only act to locally unfold or reorder the effector at the 
chaperone binding domain (CBD). Whether this localized unfolding allows for the 
unfolding of the N-terminal secretion signal or makes the secretion signal more 
accessible to the ATPase is not clear. 
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Besides being unfolded, secretion of type III effectors requires an N-terminal 
secretion signal that is possibly recognized by the ATPase. However, this signal is highly 
divergent and efforts to predict secretion substrates based on their N-terminal amino acid 
composition has remained challenging. Recent studies have used machine-learning 
approaches that focused on the N-terminal25 amino acids of known type III effectors to 
predict the probability that a protein is in fact an effector[25, 30]. Predicted secretion 
signals were mostly disordered, largely hydrophobic, often with polar-hydrophobic-polar 
residue patterns, and were serine and threonine-rich. One such prediction program 
identified 86 putative C. trachamatis effectors, 24 of which had already been 
experimentally confinned to be type III effectors[30]. 
Considering the small number of possible chaperones, it is clear that not all of 
these effectors will require a chaperone for their translocation. Thus a major enigma in 
bacterial type III secretion is why some effectors require chaperones while others do not. 
In EPEC and Yersinia, a hierarchy of secretion is established in which effectors that have 
cognate chaperones are secreted preferentially to those without chaperones[62, 154, 155]. 
Since few chlamydial chaperone-effector interactions have been detected thus far, I have 
no indication as to whether such a hierarchy exists during infection, but it is easy to 
imagine how such a hierarchy could playa role in regulating Chlamydia '8 developmental 
cycle. 
The recently discovered type III secretion chaperone Mcsc was not predicted to be 
a Class I chaperone by in silica analysis, but its association with effectors and ability to 
form homodimers in a yeast 2-hybrid screen[49] led us to test its ability to interact with 
T ARP as well as its ability to form heterodimers in our bacterial 2-hybrid assays. I did 
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not detect any interaction between TARP and Mcsc, but the Mcsc-Mcsc co-expressing 
DHMI strain had nearly 6 fold higher ~-galactosidase activity than the Slcl-SIcI 
interaction and as much as 10 fold higher than other background chaperone-chaperone 
interactions. Mcsc is an atypical Class Ib chaperone that has been shown to have 
multiple effectors and also interacts with several type III C-ring components, therefore its 
role in Chlamydia infection may differ from the typical effector chaperones and cannot 
be compared directly with other Class I chaperones. 
Being associated with both type III secretion effectors and cytoplasmic 
components of the type III apparatus, the Mcsc dimer has been speculated to playa role 
in co-translational secretion of effectors [ 49]. No evidence has been presented thus far to 
suggest the coupling of effector translation and non-flagellar type III secretion in 
Chlamydia, nor in other bacteria. However, a model of flagellar secretion coupled with 
translation of the FlgM mRNA transcript has been proposed in Salmonella 
typhimurium[I56]. In addition to Mcsc's ability to interact with apparatus components, 
the Chlamydia non-flagellar type III components have also been shown to interact with 
flagellar components[I57]. Thus it is possible that the Chlamydia type III secretion 
system is capable of unique mechanisms of regulating substrate translation and 
translocation. 
Oligomerization state of SIc1 and SIc1: TARP complexes 
Further characterization of the SIc I-SIc 1 interaction was detected with cross-
linking and gel filtration chromatography. While the cross-linking with DTSSP was only 
supposed to stabilize the already formed SIc 1 homo-complexes, I contend that trimeric 
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SIc1 species were induced in the presence of the cross-linker. Purified SIcI was highly 
concentrated in our samples and separate molecules of SIc I were likely in close enough 
contact to become cross-linked. The most revealing aspect of the cross-linking assay was 
the finding that SIc I homo-dimers could be detected on a non-reducing SDS-PAGE gel 
even without cross-linking treatment. 
Gel filtration chromatography only confirmed our hunch that native SIcI forms 
stable dimeric species in solution. A single native SIc I complex migrated through the 
sepharose column to a position corresponding to a molecular weight of approximately 40 
kDa, which is certainly indicative of homo-dimers. However, gel filtration 
chromatography is sensitive to both the size and molecular weight of the sample, so I 
cannot pinpoint an exact molecular weight with this assay. This approach was also useful 
for detecting the native SIc I : T ARP complex. I expected to find a complex of a 
combined molecular weight of ~ 65 kDa (2 chaperone molecules to I TARP), but the 
SIcI and TARP-containing elution fractions corresponded to a size >75 kDa. One reason 
for this larger size could be that the complex actually has a stoichiometry of2:2, however 
this is unlikely considering the plethora of crystallization data supporting a 2: I 
stoichiometry for type III chaperone: effector complexes. Instead I claim that the 
partially unfolded T ARP in combination with the chaperone dimer has an extended size 
that caused the complex to elute earlier than expected from the sepharose column. The 
importance of this 2:1 stoichiometry in mediating the interaction with the type III 
secretion apparatus is not III understood, but it is certainly an area worth investigating 
considering both Class II and Class III chaperones also form dimers to interact with their 
substrates[153]. The conservation of this chaperone dimer/substrate complex among 
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bacterial type III secretion systems has led to the conclusion that this complex forms a 
three dimensional secretion signal that directs it to the type III apparatus [151]. 
A three-dimensional secretion signal that could trigger recognition by the type III 
A TPase has been proposed multiple times, but only a recent study was able to 
demonstrate the role of a chaperone-mediated translocation signal. The type III effector 
YopE from Yersinia pseudotuberculosis was dependent on a solvent exposed patch 
corresponding to the chaperone-binding domain for translocation, but interestingly these 
solvent exposed residues were not essential for chaperone binding[158]. This finding 
indicated that the type III chaperone orders the chaperone-binding domain of the effector 
such that a second secretion signal is exposed on the effector surface. Further work with 
type III chaperone-effector complexes that have been previously crystallized will indicate 
if the chaperone-mediated solvent-exposed patch is the universal three-dimensional 
translocation signal. 
Considering that Chlamydia has two possible type III ATPases (CdsN and FliA) 
that are expressed during infection, it is probable that there is a difference in effector 
recognition between these A TPases[35]. Whether these A TPases (or possibly 
combinations of cytoplasmic type III components) would be able to differentiate between 
N -terminal secretion signals (S 1) and/or chaperone-mediated translocation signals (S2) is 
yet to be determined. Thus future experiments testing the interaction of alternate 
chlamydial A TPases with chaperone-substrate complexes in vitro and in heterologous 
systems will be revealing as to the importance of different secretion signals in type III 
effector recognition, as well as clue us in to possible ATPase switching during actual 
infection. Speculation about ATPase switching may seem far-fetched when considering 
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the complete lack of precedence in other known bacterial type III secretion systems. 
However since the chlamydial type III secretion systems have evolved in isolation from 
the Proteobacteria for more than 2 billion years there will almost certainly be 
Chlamydia-specific type III interactions and functions that are not present in the other 
gram-negative type III secretion systems[22]. 
Roles for chaperone-effector interactions in developmental cycle regulation 
As mediators of translocation type III chaperones may play an important role in 
the regulation of the EB to RB and/or RB to EB transitions that are necessary for 
establishing infection and spreading to surrounding tissues. Release of an effector, such 
as TARP, may allow for interaction of its cognate chaperone, Slc 1, with another effector, 
whose translocation could trigger post-invasion events. Such an ordered process could 
conceivably be maintained by the specificity of the effectors' chaperone binding domain 
for a specific chaperone dimer. CesT for instance, in EPEC, is known to act as chaperone 
for multiple effectors, having the highest affinity for the invasion-associated effector Tir, 
which is also the first of its cognate effectors to be detected in the host cell[159]. 
The apparent interaction of the chlamydial chaperone Slc2 (CT663) with both 
E.coli RNA polymerase (RNAP) and the chlamydial major sigma factor a 66 indicates a 
possible regulatory role for type III chaperones[159]. It is tempting to speculate that the 
Slc2 interaction with a66 of the chlamydial RNAP holoenzyme allows for subsequent 
gene transcription by the alternate sigma factor a28, possibly initiating transcription of a 
set of genes involved in the RB to EB differentiation or maintaining the persistent RB. 
Both CT663 and the a28 -encoding gene fliA are mid-cycle genes and therefore their 
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expressed products are likely to playa role in late developmental cycle events[93]. The 
Slc2-Scc 1 interaction detected in two-hybrid studies may sequester Slc2 and prevent it 
from acting as an anti-sigma factor during specific stages of infection. Determination of 
Scc l' s cognate effector or function during infection may provide insight into how and 
when Slc2 could act to regulate transcription. However, this area definitely needs to be 
further investigated to really determine the importance of Slc2 in gene regulation. 
Dependence of TARP's translocation on SlcJ in heterologous systems 
While our biochemical assays only serve to indicate protein-protein interactions 
between putative chlamydial type III chaperones and between the chaperone SIc 1 and the 
invasion-associated effector T ARP, the findings beget many possible roles for these 
interactions during infection. I contend that Slc l' s main role is to achieve translocation of 
its cognate effector TARP and subsequently ensure the efficient uptake of Chlamydia by 
non-phagocytic eukaryotes. Using several different heterologous bacterial type III 
secretion systems I attempted to determine the chaperone requirement for T ARP 
translocation. Translocation of p-Iactamase fused effectors was reported by the cleavage 
of a lipophilic p-Iactam ring-containing compound CCF21 AM. Because excitation of the 
cleaved and non-cleaved substrates at 410 nm produced emissions of alternate 
fluorescence wavelengths (510 nm and 450 nm, respectively), I was able to accurately 
measure T ARP translocation into a population of HeLa cells by a ratio of fluorescence. 
This CCF21 AM based translocation assay has been widely used for detecting 
translocation of type III and type IV secreted effectors by Shigella, Legionella, 
Salmonella, Yersinia, E. coli, and Pseuodomonas[ 160-163]. 
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The reproducibility of this assay is based in the fact that total fluorescence is 
measured from a population of infected HeLa cells, so as long the multiplicities of 
infection are equal among compared samples, then the differences in substrate absorption 
and number of cells in each III are cancelled out when the fluorescence ratios are 
calculated. I was able to detect translocation of p-Iactamase-fused T ARP by Yersinia 
enterocolitica and the SPI-2 system of Salmonella typhimurium. Co-expression with its 
cognate chaperone significantly increased TARP translocation by both species. 
However, I was unable to detect any TARP translocation by enterropathogenic 
E. coli or by the SPI -1 system of S. typhimurium, even in the presence of Slc 1. Secretion 
or translocation of chlamydial type III effectors had been previously reported with the 
SPI-I, SPI-2, and Y eneterocolitica type III systems, but not with EPEC. One possible 
reason for the lack of T ARP translocation by EPEC could be that its ATPase recognizes a 
different N-terminal secretion signal. Alternatively, it could be that a chlamydial 
chaperone-mediated three-dimensional secretion signal cannot be recognized by the 
EPEC type III apparatus. 
It has been previously shown that some chlamydial effectors are preferentially 
translocated by the heterologous SPI-1 or SPI-2 type III secretion systems[43]. Similarly, 
in our translocation assays I see a preference for translocation of T ARP by the SPI -2 
system. However, the fluorescence ratio had previously only been applied to measure the 
translocation of effectors within a few hours of infection, and the SPI-2 secretion system 
translocates effectors from its intracellular Salmonella containing vesicle between 6 and 
10 hours post-infection[161]. I had to consider the possibility the some of the CCF21 AM 
substrate was able to access the non-translocated p-Iactamase-fused effectors inside the 
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intracellular Salmonella, thus leading to a background level of cleaved substrate in this 
assay. SPI-2 translocation of ~-lactamase fused effectors had been demonstrated 
previously but instead of calculating a fluorescence ratio, they observed blue and green 
fluorescence by live-cell microscopy[159]. Their microscopy results revealed a low level 
of conversion of the green to blue signal, but they were still able to obviously distinguish 
between cells in which a ~-lactamase fused effector had been translocated (blue) from 
cells with no translocation (green). This background level of cleavage falsely skews the 
fluorescence ratio to indicate translocation in the (Empty) ~-lactamase vector only 
negative control. However, I still believe that the elevated fluorescence ratio for T ARP 
in the presence of SIc1 is significantly higher than this background, indicating actual 
chaperone-mediated translocation by the SPI-2 secretion system of S. typhimurium. 
Secretion of T ARP into media had been previously demonstrated by Y 
pseudotuberculosis[42], and I was able to confirm Yersinia's ability to secrete TARP by 
Y enterocolitica. However, TARP's translocation into eukaryotic cells had not 
previously been tested, and even though T ARP is secreted into media without a 
chaperone, secretion and translocation of effectors by Yersinia has been shown to have 
differential requirements for chaperones[62]. It has been shown that for Yersinia 
effectors, the N-terminal secretion signal is sufficient for secretion into low-calcium 
media, while translocation of effectors into host cells requires their cognate chaperones. 
This dogma is in agreement with our findings that T ARP is secreted into media similarly 
to the positive control Yersinia effector Y opH, but T ARP requires SIc 1 to be efficiently 
translocated into host cells. 
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I perfonned phylogenetic analysis of cytoplasmic type III flagellar and non-
flagellar A TPases from C. trachomatis and c.pneumoniae in comparison with the SPI-I 
and SPI-2 ATPases from S.typhimurium, EscN from EPEC, and YscN from Y 
enterocolitica to assess whether the relatedness of A TPases could explain TARP 
translocation differences. The chlamydial non-flagellar ATPase CdsN was more closely 
related to YscN than InvC, SsaN, or EscN. This finding agrees with the fact that 
Yenterocolitica was able to secrete and translocate TARP. The SIc I-dependence of 
T ARP for efficient translocation of Yersinia indicates that the SIc 1: TARP complex 
interacts with Y scN in much the same way as it interacts with CdsN during chlamydial 
infection. Since TARP is capable of being translocated by the Salmonella SPI-2 type III 
secretion system but not by the SPI -1 system, it was interesting to note that the SPI -2 
ATPase ssaN was more closely related to CdsN than the SPI -1 ATPase InvC. These 
phylogenetic comparisons of type III A TPases imply that the SIc 1: TARP complex is also 
likely to be able to interact with chlamydial CdsN. The agreement between ATPase 
phylogeny and functional interaction with the effector T ARP gives credibility to our 
heterologous translocation assays. 
Taken together, these findings indicate a role for SIc 1 in the translocation of 
TARP by the chlamydial type III secretion apparatus (Figure 38). 
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Figure 38. Model of Slcl-mediated translocation of T ARP into eukaryotic cells. 
In the chlamydial EB, SIc1 associates with the N-terminus of TARP to reorganize its 
chaperone binding domain, which in tum is recognized by the type III secretion 
apparatus. Further unfolding by the ATPase allows TARP translocation through the type 
III secretion apparatus and into the eukaryotic cytosol where molecules of TARP form 
aggregates. Multiple domains on T ARP are involved in actin polymerization that 
facilitates invasion of eukaryotic cells. TARP aggregates are nucleate actin at their 
WH2-like domains, while the tyrosine rich repeats become phosphorylated by host 
kinases. These phosphorylate repeats act as magnets for host signaling molecules and 
recruit further kinases guanine exchange factors that are involved in Rac activation and 
subsequent Arp2/3 formation. 
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CONCLUSIONS 
This dissertation presents the first indication of a type III secretion chaperone 
mediating the translocation of a chlamydial effector into the cytosol of its target host cell. 
Importantly, this translocated effector, TARP, has been shown to be essential for 
ensuring the efficient invasion of non-phagocytic cells and subsequently enabling 
Chlamydia to propagate. Not only does the requirement of the chaperone SIcI in TARP 
translocation indicate a similar mechanism of effector translocation as detected in other 
type III-containing organisms, it also reveals the function of a previously uncharacterized 
protein, which is not an easy feat considering the genetically-intractable nature of 
Chlamydia spp. 
Biochemical characterization of the specific interaction between SIc 1 and TARP 
indicate a chaperone-mediated translocation signal that is likely recognized by a type III 
A TPase. Detection of this translocation by the heterologous Salmonella SPI -2 and Y 
enterocolitica type III secretion systems but not by enterropathogenic E.coli or the 
Salmonella SPI-1 systems reveals a common mechanism for the chaperone-effector 
recognition by type III components. Comparison of the A TPases between these species 
indicates a role for the chlamydial ATPase CdsN in recognition of the SIc 1: TARP 
complex. Further characterization the interaction of CdsN with this complex as well as 
other type III chaperone: substrate complexes may define a mechanism of differential 
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selection of type III substrates for translocation such as the recognition of three-
dimensional chaperone-substrate translocation signals. 
Recent work has demonstrated the inhibition of chlamydial growth and division 
by chemical inhibitors of type III secretion. The exact mechanism of this inhibition is 
unknown, and a likely target of these and future inhibition studies is the type III ATPase. 
Mapping the specific interactions that direct substrate recognition in the presence and 
absence of the type III chaperones will be pivotal to guiding the design of type III 
inhibitors for basic research and possibly for antibiotic use against several gram-negative 
pathogens. 
The conservation of the type III secretion system among distantly related 
pathogenic and environmental Chlamydiaceae, all of which exhibit the biphasic 
intracellular lifestyle, indicates a role for the type III secretion system in maintaining this 
common lifestyle. Type III inhibitor studies will also provide valuable insight in the 
mechanisms directing the regulation of the Chlamydia'S unique biphasic developmental 
cycle. Substrate-switching, chaperone-mediated translocation hierarchies, interaction of 
type III components with transcription machinery, and sequestering of type III 
chaperones or substrates are all potential mechanisms that Chlamydia spp. may exploit to 
ensure efficient survival and transitioning between infectious (EB) and replicating (RB) 
forms. 
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